

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 8 JAN 30 Saved answer limit increased  
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 11 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality  
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral  
property data  
NEWS 16 MAR 01 INSPEC reloaded and enhanced  
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 19 MAR 22 EMBASE is now updated on a daily basis  
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:49:58 ON 10 APR 2006

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:50:18 ON 10 APR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 9 APR 2006 HIGHEST RN 879846-78-3  
 DICTIONARY FILE UPDATES: 9 APR 2006 HIGHEST RN 879846-78-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> E "BENZYL METHACRYLATE"/CN 25
E1      1      BENZYL MESYLGLYCINATE/CN
E2      1      BENZYL METAPHOSPHATE, (PHCH2O)PO2/CN
E3      1 --> BENZYL METHACRYLATE/CN
E4      1      BENZYL METHACRYLATE HOMOPOLYMER/CN
E5      1      BENZYL METHACRYLATE POLYMER/CN
E6      1      BENZYL METHACRYLATE POLYMER WITH METHYL METHACRYLATE/CN
E7      1      BENZYL METHACRYLATE TELOMER WITH THIOGLYCOLIC ACID/CN
E8      1      BENZYL METHACRYLATE TELOMER WITH THIOSALICYLIC ACID/CN
E9      1      BENZYL METHACRYLATE-(DIMETHYLAMINO)ETHYL METHACRYLATE BLOCK
COPOLYMER/CN
E10     1      BENZYL METHACRYLATE-(N,N-DIMETHYLAMINO)ETHYL METHACRYLATE BLOCK
COPOLYMER/CN
E11     1      BENZYL METHACRYLATE-(PERFLUORO)OCTYLETHYL ACRYLATE COPOLYMER/CN
E12     1      BENZYL METHACRYLATE--METHACRYLIC ACID-METHYL
METHACRYLATE-2,2,3,3-TETRAFLUOROPROPYL METHACRYLATE COPOLYMER/CN
E13     1      BENZYL METHACRYLATE-B-METHACRYLOYLOXYETHYL HYDROGEN
PHTHALATE-METHACRYLIC ACID COPOLYMER GLYCIDYL METHACRYLATE ESTER/CN
E14     1      BENZYL METHACRYLATE-Ω-CARBOXYLPOLYCAPROLACTONE
MONOACRYLATE-GLYCEROL MONOMETHACRYLATE-METHACRYLIC ACID-N-PHENYLMALIMIDE-STYRENE
COPOLYMER/CN
E15     1      BENZYL
METHACRYLATE-1,1-BIS(TRIMETHYLSILOXY)-2-METHYL-1-PROPENE-ETHOXYTRIETHYLENE GLYCOL
METHACRYLATE-TRIMETHYLSILYL METHACRYLATE BLOCK COPOLYMER/CN
```

E16 1 BENZYL  
METHACRYLATE-1,2-BIS(METHACRYLOYLTHIO)ETHANE-2,4,6-TRIBROMOPHENYL METHACRYLATE  
COPOLYMER/CN  
E17 1 BENZYL METHACRYLATE-1,2-BIS(METHACRYLOYLTHIO)ETHANE-STYRENE  
COPOLYMER/CN  
E18 1 BENZYL METHACRYLATE-1,3-BUTADIENE-BUTYL METHACRYLATE-KAYARAD  
DPHA-METHACRYLIC ACID-R 1302 COPOLYMER/CN  
E19 1 BENZYL METHACRYLATE-1,3-BUTADIENE-GLYCIDYL METHACRYLATE-MALEIC  
ANHYDRIDE-METHACRYLIC ACID COPOLYMER/CN  
E20 1 BENZYL METHACRYLATE-1,3-BUTADIENE-ITACONIC ACID-A-METHYLSTYRENE  
COPOLYMER ESTER WITH 6,7-EPOXYHEPTYL A-ETHYLACRYLATE/CN  
E21 1 BENZYL METHACRYLATE-1,3-BUTADIENE-METHACRYLIC ACID-STYRENE  
COPOLYMER/CN  
E22 1 BENZYL METHACRYLATE-1,3-BUTANEDIOL-BUTYL  
METHACRYLATE-DIMETHYLAMINOETHYL METHACRYLATE-GLYCIDYL METHACRYLATE-STYRENE-SUCCINIC  
ANHYDRIDE POLYMER/CN  
E23 1 BENZYL METHACRYLATE-1,3-BUTYLENE GLYCOL  
DIMETHACRYLATE-METHACRYLIC ACID-N,N'-PHENYLENEBISMALEIMIDE COPOLYMER/CN  
E24 1 BENZYL METHACRYLATE-1,3-PROPANEDIOL GRAFT COPOLYMER/CN  
E25 1 BENZYL  
METHACRYLATE-1,4-BIS(METHACRYLOYLTHIOMETHYL)BENZENE-STYRENE-TETRAETHYLENEGLYCOL  
DIMETHACRYLATE COPOLYMER/CN

=> S E3

L1 1 "BENZYL METHACRYLATE"/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 2495-37-6 REGISTRY

CN 2-Propenoic acid, 2-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Methacrylic acid, benzyl ester (6CI, 7CI, 8CI)

OTHER NAMES:

CN Acryester BZ

CN Benzyl 2-methyl-2-propenoate

CN Benzyl 2-methylacrylate

CN Benzyl methacrylate

CN BzMA

CN Light Ester BZ

CN NSC 20970

FS 3D CONCORD

DR 2696-41-5

MF C11 H12 O2

CI COM

LC STN Files: AQUIRE, BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT,  
CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM\*, IFICDB, IFIUDB,  
MSDS-OHS, PIRA, SPECINFO, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Caplus document type: Conference; Journal; Patent; Report

RL.P Roles from patents: BIOL (Biological study); MSC (Miscellaneous); PREP  
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP  
(Preparation); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP  
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical

study); PREP (Preparation); PRP (Properties); USES (Uses)

/ Structure 1 in file .gra /

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

457 REFERENCES IN FILE CA (1907 TO DATE)  
115 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
457 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.54

7.75

FILE 'CAPLUS' ENTERED AT 15:51:20 ON 10 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2006 VOL 144 ISS 16

FILE LAST UPDATED: 9 Apr 2006 (20060409/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1

L2 457 L1

=> s phosphorylcholine

3870 PHOSPHORYLCHOLINE

81 PHOSPHORYLCHOLINES

L3 3894 PHOSPHORYLCHOLINE

(PHOSPHORYLCHOLINE OR PHOSPHORYLCHOLINES)

=> s l3 adn l2

MISSING OPERATOR L3 ADN

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l3 and l2

L4 0 L3 AND L2

=> s l2 and agglutination

13927 AGGLUTINATION

136 AGGLUTINATIONS

13980 AGGLUTINATION

(AGGLUTINATION OR AGGLUTINATIONS)



L5 0 L2 AND AGGLUTINATION

=> s l2 and assay  
346810 ASSAY  
151851 ASSAYS  
456150 ASSAY

(ASSAY OR ASSAYS)

L6 5 L2 AND ASSAY

=> d ibib 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:231684 CAPLUS  
DOCUMENT NUMBER: 140:370087  
TITLE: Assessment and Modeling of the Toxicity of Organic  
Chemicals to *Chlorella vulgaris*: Development of a  
Novel Database  
AUTHOR(S): Cronin, Mark T. D.; Netzeva, Tatiana I.; Dearden, John  
C.; Edwards, Robert; Worgan, Andrew D. P.  
CORPORATE SOURCE: School of Pharmacy and Chemistry, Liverpool John  
Moores University, Liverpool, L3 3AF, UK  
SOURCE: Chemical Research in Toxicology (2004), 17(4), 545-554  
CODEN: CRTOEC; ISSN: 0893-228X  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:876871 CAPLUS  
DOCUMENT NUMBER: 140:37245  
TITLE: QSAR Analysis of the Toxicity of Aromatic Compounds to  
*Chlorella vulgaris* in a Novel Short-Term Assay  
AUTHOR(S): Netzeva, Tatiana I.; Dearden, John C.; Edwards,  
Robert; Worgan, Andrew D. P.; Cronin, Mark T. D.  
CORPORATE SOURCE: School of Pharmacy and Chemistry, Liverpool John  
Moores University, Liverpool, L3 3AF, UK  
SOURCE: Journal of Chemical Information and Computer Sciences  
(2004), 44(1), 258-265  
CODEN: JCISD8; ISSN: 0095-2338  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:293738 CAPLUS  
DOCUMENT NUMBER: 139:192609  
TITLE: An exploratory study of the use of multivariate  
techniques to determine mechanisms of toxic action  
AUTHOR(S): Ren, Shijin; Frymier, Paul D.; Schultz, T. Wayne  
CORPORATE SOURCE: 331 Stokely Management Center, Department of  
Statistics, University of Tennessee, Knoxville, TN,  
37996-0532, USA  
SOURCE: Ecotoxicology and Environmental Safety (2003), 55(1),  
86-97  
CODEN: EESADV; ISSN: 0147-6513  
PUBLISHER: Elsevier Science  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:53082 CAPLUS  
DOCUMENT NUMBER: 130:233374  
TITLE: Comparison of Tetrahymena and Pimephales toxicity  
based on mechanism of action  
AUTHOR(S): Bearden, A. P.; Schultz, T. W.  
CORPORATE SOURCE: Waste Management Research and Education Institute;  
Graduate program in Ecology and Evolutionary Biology,  
The University of Tennessee, Knoxville, TN,  
37901-1071, USA  
SOURCE: SAR and QSAR in Environmental Research (1998), 9(3-4),  
127-153  
CODEN: SQERED; ISSN: 1062-936X  
PUBLISHER: Gordon & Breach Science Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1996:400377 CAPLUS  
DOCUMENT NUMBER: 125:150999  
TITLE: Genotoxicity of dental materials  
AUTHOR(S): Heil, Juergen; Reifferscheid, Georg; Waldmann, Petra;  
Leyhausen, Gabriele; Geurtsen, Werner  
CORPORATE SOURCE: AMMUG, Universitaet Mainz, Obere Zahlbacher Str. 63,  
Mainz, D-55101, Germany  
SOURCE: Mutation Research (1996), 368(3,4), 181-194  
CODEN: MUREAV; ISSN: 0027-5107  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.39	21.14

STN INTERNATIONAL LOGOFF AT 15:53:40 ON 10 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 8 JAN 30 Saved answer limit increased  
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 11 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 13 FEB 28 MEDLINE/IMEDLINE reload improves functionality  
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral  
property data  
NEWS 16 MAR 01 INSPEC reloaded and enhanced  
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 19 MAR 22 EMBASE is now updated on a daily basis  
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:52:40 ON 12 APR 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:52:53 ON 12 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2006 HIGHEST RN 879997-63-4  
DICTIONARY FILE UPDATES: 10 APR 2006 HIGHEST RN 879997-63-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> E "BIOTINAMIDOCAPROATE-N-HYDROXYSUCCINIMIDE"/CN 25
E1      1      BIOTIN/LIPOYL ATTACHMENT:HMG-COA LYASE-LIKE:BIOTIN-REQUIRING
ENZYME, ATTACHMENT SITE: CARBOXYLASE REGION:CARBAMOYL-P... (BRUCELLA MELITENSIS
BIOVAR ABORTUS STRAIN 2308 GENE PYC)/CN
E2      1      BIOTINAMIDE/CN
E3      0  --> BIOTINAMIDOCAPROATE-N-HYDROXYSUCCINIMIDE/CN
E4      1      BIOTINAMIDOCAPROYL HYDRAZIDE/CN
E5      1      BIOTINE SYNTHASE (GENE BIOB) (CLOSTRIDIUM ACETOBUTYLICUM STRAIN
ATCC 824 GENE CAC0210)/CN
E6      1      BIOTINHYDROXAMIC ACID/CN
E7      1      BIOTINIDASE/CN
E8      1      BIOTINIDASE (CATTLE PRECURSOR C-TERMINAL FRAGMENT)/CN
E9      1      BIOTINIDASE (DROSOPHILA MELANOGASTER GENE CG3599)/CN
E10     1      BIOTINIDASE (HUMAN CLONE BTD2000 )/CN
E11     1      BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR REDUCED)/CN
E12     1      BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR) (E.C.3.5.1.12)/CN
E13     2      BIOTINIDASE (HUMAN GENE BTD)/CN
E14     1      BIOTINIDASE (MACACA MULATTA PRECURSOR C-TERMINAL FRAGMENT)/CN
E15     1      BIOTINIDASE (MOUSE PRECURSOR C-TERMINAL FRAGMENT)/CN
E16     1      BIOTINIDASE (MOUSE STRAIN FVB/N CLONE MGC:35781 IMAGE:5099802)/CN
E17     2      BIOTINIDASE (ONCORHYNCHUS MYKISS LIVER FRAGMENT)/CN
E18     1      BIOTINIDASE (RAT PRECURSOR C-TERMINAL FRAGMENT)/CN
E19     1      BIOTINIDASE, PRECURSOR (HUMAN CLONE MGC:20073 IMAGE:4559618)/CN
E20     1      BIOTININ/CN
E21     1      BIOTINOL/CN
E22     1      BIOTINOYL 5'-ADENYLATE/CN
E23     1      BIOTINYL 5'-AMP/CN
E24     1      BIOTINYL CADAVERINE/CN
E25     1      BIOTINYL COA SYNTHETASE/CN
```

```
=> E "BIOTINAMIDOCAPROATE"/CN 25
E1      1      BIOTIN/LIPOYL ATTACHMENT:HMG-COA LYASE-LIKE:BIOTIN-REQUIRING
ENZYME, ATTACHMENT SITE: CARBOXYLASE REGION:CARBAMOYL-P... (BRUCELLA MELITENSIS
BIOVAR ABORTUS STRAIN 2308 GENE PYC)/CN
```

E2 1 BIOTINAMIDE/CN  
E3 0 --> BIOTINAMIDOCAPROATE/CN  
E4 1 BIOTINAMIDOCAPROYL HYDRAZIDE/CN  
E5 1 BIOTINE SYNTHASE (GENE BIOB) (CLOSTRIDIUM ACETOBUTYLICUM STRAIN  
ATCC 824 GENE CAC0210)/CN  
E6 1 BIOTINHYDROXAMIC ACID/CN  
E7 1 BIOTINIDASE/CN  
E8 1 BIOTINIDASE (CATTLE PRECURSOR C-TERMINAL FRAGMENT)/CN  
E9 1 BIOTINIDASE (DROSOPHILA MELANOGASTER GENE CG3599)/CN  
E10 1 BIOTINIDASE (HUMAN CLONE BTD2000 )/CN  
E11 1 BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR REDUCED)/CN  
E12 1 BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR) (E.C.3.5.1.12)/CN  
E13 2 BIOTINIDASE (HUMAN GENE BTD)/CN  
E14 1 BIOTINIDASE (MACACA MULATTA PRECURSOR C-TERMINAL FRAGMENT)/CN  
E15 1 BIOTINIDASE (MOUSE PRECURSOR C-TERMINAL FRAGMENT)/CN  
E16 1 BIOTINIDASE (MOUSE STRAIN FVB/N CLONE MGC:35781 IMAGE:5099802)/CN  
E17 2 BIOTINIDASE (ONCORHYNCHUS MYKISS LIVER FRAGMENT)/CN  
E18 1 BIOTINIDASE (RAT PRECURSOR C-TERMINAL FRAGMENT)/CN  
E19 1 BIOTINIDASE, PRECURSOR (HUMAN CLONE MGC:20073 IMAGE:4559618)/CN  
E20 1 BIOTININ/CN  
E21 1 BIOTINOL/CN  
E22 1 BIOTINOYL 5'-ADENYLATE/CN  
E23 1 BIOTINYL 5'-AMP/CN  
E24 1 BIOTINYL CADAVERINE/CN  
E25 1 BIOTINYL COA SYNTHETASE/CN

=> E "BIOTINAMIDOCAPROATE N-HYDROXYSUCCINIMIDE ESTER "/CN 25

E1 1 BIOTIN/LIPOYL ATTACHMENT:HMG-COA LYASE-LIKE:BIOTIN-REQUIRING  
ENZYME, ATTACHMENT SITE: CARBOXYLASE REGION:CARBAMOYL-P... (BRUCELLA MELITENSIS  
BIOVAR ABORTUS STRAIN 2308 GENE PYC)/CN  
E2 1 BIOTINAMIDE/CN  
E3 0 --> BIOTINAMIDOCAPROATE N-HYDROXYSUCCINIMIDE ESTER /CN  
E4 1 BIOTINAMIDOCAPROYL HYDRAZIDE/CN  
E5 1 BIOTINE SYNTHASE (GENE BIOB) (CLOSTRIDIUM ACETOBUTYLICUM STRAIN  
ATCC 824 GENE CAC0210)/CN  
E6 1 BIOTINHYDROXAMIC ACID/CN  
E7 1 BIOTINIDASE/CN  
E8 1 BIOTINIDASE (CATTLE PRECURSOR C-TERMINAL FRAGMENT)/CN  
E9 1 BIOTINIDASE (DROSOPHILA MELANOGASTER GENE CG3599)/CN  
E10 1 BIOTINIDASE (HUMAN CLONE BTD2000 )/CN  
E11 1 BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR REDUCED)/CN  
E12 1 BIOTINIDASE (HUMAN CLONE BTD2000 PRECURSOR) (E.C.3.5.1.12)/CN  
E13 2 BIOTINIDASE (HUMAN GENE BTD)/CN  
E14 1 BIOTINIDASE (MACACA MULATTA PRECURSOR C-TERMINAL FRAGMENT)/CN  
E15 1 BIOTINIDASE (MOUSE PRECURSOR C-TERMINAL FRAGMENT)/CN  
E16 1 BIOTINIDASE (MOUSE STRAIN FVB/N CLONE MGC:35781 IMAGE:5099802)/CN  
E17 2 BIOTINIDASE (ONCORHYNCHUS MYKISS LIVER FRAGMENT)/CN  
E18 1 BIOTINIDASE (RAT PRECURSOR C-TERMINAL FRAGMENT)/CN  
E19 1 BIOTINIDASE, PRECURSOR (HUMAN CLONE MGC:20073 IMAGE:4559618)/CN  
E20 1 BIOTININ/CN  
E21 1 BIOTINOL/CN  
E22 1 BIOTINOYL 5'-ADENYLATE/CN  
E23 1 BIOTINYL 5'-AMP/CN  
E24 1 BIOTINYL CADAVERINE/CN  
E25 1 BIOTINYL COA SYNTHETASE/CN

=> E "BNHS"/CN 25

E1 1 BNF 4/CN  
E2 1 BNH PROTEIN (PECTINESTERASE-LIKE PROTEIN) (POLLEN-SECIFIC  
PROTEIN-LIKE) (ARABIDOPSIS THALIANA STRAIN COLUMBIA CLONE MRP15)/CN  
E3 0 --> BNHS/CN  
E4 1 BNI/CN  
E5 1 BNI 11/CN  
E6 1 BNI 4/CN  
E7 1 BNI 5/CN

E8	1	BNI 6/CN
E9	1	BNI 7/CN
E10	1	BNI-1/CN
E11	1	BNI-1-150/CN
E12	1	BNI-2/CN
E13	1	BNI-50A/CN
E14	1	BNI-5B/CN
E15	1	BNI-IV/CN
E16	1	BNI-IV,OK/CN
E17	1	BNI10/CN
E18	1	BNI14.8CR8SI3P3FE/CN
E19	1	BNI1A/CN
E20	1	BNI20.3CR11.5SI0.5P/CN
E21	1	BNI21.5CR11.6SI/CN
E22	1	BNI26.3CR5.1SI3P/CN
E23	1	BNI3/CN
E24	1	BNI55PDCRB/CN
E25	1	BNI5A/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

1.32

1.53

FILE 'CAPLUS' ENTERED AT 10:54:31 ON 12 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2006 VOL 144 ISS 16

FILE LAST UPDATED: 11 Apr 2006 (20060411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> Biotinamidocaproate N-hydroxysuccinimide ester

BIOTINAMIDOCAPROATE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s Biotinamidocaproate N-hydroxysuccinimide ester

```

      24 BIOTINAMIDOCAPROATE
2899680 N
      7445 HYDROXYSUCCINIMIDE
      26 HYDROXYSUCCINIMIDES
      7452 HYDROXYSUCCINIMIDE
          (HYDROXYSUCCINIMIDE OR HYDROXYSUCCINIMIDES)
576049 ESTER
428412 ESTERS
804244 ESTER
          (ESTER OR ESTERS)

```

L1 7 BIOTINAMIDOCAPROATE N-HYDROXYSUCCINIMIDE ESTER  
(BIOTINAMIDOCAPROATE (W) N (W) HYDROXYSUCCINIMIDE (W) ESTER)

=> s rn

20261 RN  
672 RNS

L2 20909 RN  
(RN OR RNS)

=> d ll ibib 1-7

L1 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:21298 CAPLUS

DOCUMENT NUMBER: 132:262253

TITLE: In-situ monitoring of protein labeling reactions by  
matrix-assisted laser desorption/ionization mass  
spectrometry

AUTHOR(S): Lu, Jianzhong; Zenobi, Renato

CORPORATE SOURCE: Department of Chemistry, ETH Zentrum, Zurich, 8092,  
Switz.

SOURCE: Fresenius' Journal of Analytical Chemistry (2000),  
366(1), 3-9

CODEN: FJACES; ISSN: 0937-0633

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:675742 CAPLUS

DOCUMENT NUMBER: 132:1668

TITLE: Controlled layer-by-layer immobilization of  
horseradish peroxidase

AUTHOR(S): Rao, Srivatsa V.; Anderson, Kimberly W.; Bachas,  
Leonidas G.

CORPORATE SOURCE: Department of Chemical and Materials Engineering,  
University of Kentucky, Lexington, KY, 40506, USA

SOURCE: Biotechnology and Bioengineering (1999), 65(4),  
389-396

CODEN: BIBIAU; ISSN: 0006-3592

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:206965 CAPLUS

DOCUMENT NUMBER: 128:319850

TITLE: In vitro association of six oviductal fluid proteins  
with the bovine zona pellucida

AUTHOR(S): Staros, A. L.; Killian, G. J.

CORPORATE SOURCE: Dairy Breeding Research Center, Department of Dairy  
and Animal Science, The Pennsylvania State University,  
University Park, PA, 16802, USA

SOURCE: Journal of Reproduction and Fertility (1998), 112(1),  
131-137

CODEN: JRPFA4; ISSN: 0022-4251

PUBLISHER: Journals of Reproduction and Fertility Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1997:28915 CAPLUS  
DOCUMENT NUMBER: 126:101423  
TITLE: Preparation of biotinylated lectins and application in  
microtiter plate assays and Western blotting  
AUTHOR(S): Lisowska, Elwira; Duk, Maria; Wu, Albert M.  
CORPORATE SOURCE: Switz.  
SOURCE: BioMethods (Basel) (1996), 7(Laboratory Guide to  
Biotin-Labeling in Biomolecule Analysis), 115-129  
CODEN: BMTHED; ISSN: 1018-6255  
PUBLISHER: Birkhaeuser  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L1 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1996:195716 CAPLUS  
DOCUMENT NUMBER: 124:254893  
TITLE: Microtiter-plate enzyme-linked ligand-sorbent assay of  
riboflavin (vitamin B2) in human plasma and urine  
AUTHOR(S): Kozik, Andrzej  
CORPORATE SOURCE: Jan Zurzychi Institute Molecular Biology, Jagiellonian  
University, Krakow, 31-120, Pol.  
SOURCE: Analyst (Cambridge, United Kingdom) (1996), 121(3),  
333-7  
CODEN: ANALAO; ISSN: 0003-2654  
PUBLISHER: Royal Society of Chemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L1 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1994:696250 CAPLUS  
DOCUMENT NUMBER: 121:296250  
TITLE: Detection of plant calmodulin-binding proteins with  
biotinylated calmodulin probe  
AUTHOR(S): Li, Jia-Xu; Bai, Juan; Wang, Xue-Chen; Sun, Da-Ye  
CORPORATE SOURCE: Department of Biology, Hebei Normal University,  
Shijiazhuang, 050016, Peop. Rep. China  
SOURCE: Zhiwu Shengli Xuebao (1994), 20(2), 157-62  
CODEN: CWSPDA; ISSN: 0257-4829  
DOCUMENT TYPE: Journal  
LANGUAGE: Chinese

L1 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1991:485755 CAPLUS  
DOCUMENT NUMBER: 115:85755  
TITLE: Novel vasopressin receptor ligands  
AUTHOR(S): Howl, John; Kerr, Ian; Chan, Conrad H. W.; Wheatley,  
Mark  
CORPORATE SOURCE: Sch. Biochem., Univ. Birmingham, Birmingham, B15 2TT,  
UK  
SOURCE: Biochemical Society Transactions (1991), 19(2), 87S  
CODEN: BCSTB5; ISSN: 0300-5127  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=>

---Logging off of STN---

=>

Executing the logoff script...



=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.65	20.18

STN INTERNATIONAL LOGOFF AT 10:56:00 ON 12 APR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 08	X.25 communication option no longer available after June 2006
NEWS 10	MAR 22	EMBASE is now updated on a daily basis
NEWS 11	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 12	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 13	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS 14	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 15	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 16	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 17	MAY 10	CA/Caplus enhanced with 1900-1906 U.S. patent records
NEWS 18	MAY 11	KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:06:18 ON 12 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:06:28 ON 12 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2006 HIGHEST RN 883943-03-1

DICTIONARY FILE UPDATES: 11 MAY 2006 HIGHEST RN 883943-03-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s LPY/SQEP

1 LPY/SQEP  
2335 SQL=3  
L1 1 LPY/SQEP  
(LPY/SQEP AND SQL=3)

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.49	7.70

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:06:51 ON 12 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 11 May 2006 (20060511/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1

L2 1 L1

=> d ibib

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1992:143387 CAPLUS  
DOCUMENT NUMBER: 116:143387  
TITLE: A specific binding site in Nb2 node lymphoma cells  
mediates the effects of didemnin B, an  
immunosuppressive cyclic peptide  
AUTHOR(S): Shen, Gary K.; Zukoski, Charles F.; Montgomery, David  
W.  
CORPORATE SOURCE: Dep. Surg., Arizona Health Sci. Cent., Tucson, AZ,  
85724, USA  
SOURCE: International Journal of Immunopharmacology (1992),  
14(1), 63-73  
CODEN: IJIMDS; ISSN: 0192-0561  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.60	9.30

STN INTERNATIONAL LOGOFF AT 15:07:40 ON 12 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 08	X.25 communication option no longer available after June 2006
NEWS 10 MAR 22	EMBASE is now updated on a daily basis
NEWS 11 APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 12 APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 13 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS 14 APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 15 APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 16 APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 17 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 18 MAY 11	KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:19:24 ON 12 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:19:34 ON 12 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2006 HIGHEST RN 883943-03-1

DICTIONARY FILE UPDATES: 11 MAY 2006 HIGHEST RN 883943-03-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s RLLDTNRPLLPY/sqep
      1 RLLDTNRPLLPY/SQEP
193854 SQL=12
L1      1 RLLDTNRPLLPY/SQEP
      (RLLDTNRPLLPY/SQEP AND SQL=12)
```

```
=> s RLLDTNRPLLPY/sqsp
L2      1 RLLDTNRPLLPY/SQSP
```

```
=> file caplus
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                35.94      36.15
```

FILE 'CAPLUS' ENTERED AT 15:20:15 ON 12 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 11 May 2006 (20060511/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l1
L3      2 L1
```

```
=> d ibib 1-2
```

```
L3  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:    2005:34642  CAPLUS
DOCUMENT NUMBER:     142:120467
TITLE:               Peptide marker targeting to nasopharyngeal carcinoma
                     cell and application thereof
INVENTOR(S):         Wu, Han-chung; Lin, Chin-tarng; Lee, Tong-young
PATENT ASSIGNEE(S):  Taiwan
SOURCE:              U.S. Pat. Appl. Publ., 15 pp.
                     CODEN: USXXCO
DOCUMENT TYPE:       Patent
LANGUAGE:            English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
US 2005010036      A1      20050113      US 2004-796892      20040309  
PRIORITY APPLN. INFO.:      TW 2003-92117944      A      20030701

L3    ANSWER 2 OF 2    CAPLUS    COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER:      2004:913617    CAPLUS  
DOCUMENT NUMBER:      142:48706  
TITLE:      A Novel Peptide Specifically Binding to Nasopharyngeal  
                 Carcinoma For Targeted Drug Delivery  
AUTHOR(S):      Lee, Tong-Young; Wu, Han-Chung; Tseng, Yun-Long; Lin,  
                 Chin-Tarn  
CORPORATE SOURCE:      Institute of Pathology, College of Medicine, National  
                 Taiwan University, Taipei, Taiwan  
SOURCE:      Cancer Research (2004), 64(21), 8002-8008  
                 CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER:      American Association for Cancer Research  
DOCUMENT TYPE:      Journal  
LANGUAGE:      English  
REFERENCE COUNT:      38      THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file dissab

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.74	38.89

FILE 'DISSABS' ENTERED AT 15:20:56 ON 12 MAY 2006

COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 28 APR 2006 (20060428/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

=> s RLLDTNRPLLPY

	0 RLLDTNRPLLPY
L4	0 RLLDTNRPLLPY

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.41	39.30

FILE 'PCTFULL' ENTERED AT 15:21:09 ON 12 MAY 2006

COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:      11 MAY 2006      <20060511/UP>  
MOST RECENT UPDATE WEEK:      200618      <200618/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

=> s RLLDTNRPLL PY  
0 RLLDTNRPLL PY  
L5 0 RLLDTNRPLL PY

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.16	40.46

FILE 'CAPLUS' ENTERED AT 15:21:20 ON 12 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 11 May 2006 (20060511/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s RLLDTNRPLL PY  
0 RLLDTNRPLL PY  
L6 0 RLLDTNRPLL PY

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.41	42.87

STN INTERNATIONAL LOGOFF AT 15:21:29 ON 12 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x



LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume.

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would  
like to better understand what you find useful. Please take  
approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you  
will be entered in a drawing to win a free iPod(R). Your responses  
will be kept confidential and will help us make future improvements  
to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:24:01 ON 15 MAY 2006

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'PCTFULL' ENTERED AT 12:24:12 ON 15 MAY 2006

COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 11 MAY 2006 <20060511/UP>

MOST RECENT UPDATE WEEK: 200618 <200618/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE

(last updated April 10, 2006) <<<

=> s WO 9741824/pn

L1 1 WO 9741824/PN  
(WO9741824/PN)

=> s l1 and conjugat?

75029 CONJUGAT?

L2 1 L1 AND CONJUGAT?

=> d kwic

L2 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN

PI WO 9741824 A2 19971113

DETD . . . therapy methods whereby DNA sequences encoding a kringle 5 peptide fragment or kringle 5 fusion protein or kringle 5 peptide fragment conjugate are introduced into a patient to modify in vivo kringle 5 levels.

. . . about 1: 300 to form a mixture of said elastase and said plasminogen; (b) incubating said mixture; and (c) isolating a protein conjugate of a kringle 5 peptide fragment from said mixture; (d) exposing said protein conjugate of the kringle 5 peptide fragment to pepsin at a ratio of about 1:0.2 to form a mixture of said pepsin. . .

As used herein, the term conjugate of a K5 peptide fragment means a kringle 5 peptide fragment chemically coupled to another protein to form a conjugate. Examples of conjugates of kringle 5 peptide fragments include a kringle 5 peptide fragment coupled to albumin or to a peptide fragment from another. . .

Molecular weights of conjugates of kringle 5 peptide fragments are between about 1,000 and about 25,000 kDa.

The present invention also encompasses gene therapy whereby the gene encoding kringle 5 peptide fragments or kringle 5 peptide fragment conjugates is regulated in a patient. Various methods of transferring or delivering DNA to cells for expression of the gene product protein, otherwise. . . .

As an example of a prophylactic strategy, a gene encoding a kringle 5 peptide fragment or a kringle 5 peptide fragment conjugate may be placed in a patient and thus prevent occurrence of angiogenesis or a gene that makes tumor cells more susceptible. . . .

method of inserting the DNA into the cells bearing that receptor. Another carrier system that has been used is the asialoglycoprotein/polylysine conjugate system for carrying DNA to hepatocytes for in vivo gene transfer.

Biological gene therapy methodologies employ viral vectors or non-viral vectors (such as the figand-DNA conjugates, liposomes and the lipid-DNA complexes discussed above) to insert genes into cells. The transfected cells may be cells derived from the. . . .

Kringle 5 peptide fragments or fusion proteins or conjugates of the present invention 1-5 can also be used as antigens to generate polyclonal or monoclonal antibodies which are specific for the. . . .

or kringle 5 fusion proteins may be labeled with radioactive isotopes (See Example 13) or chemically coupled to proteins to form conjugates.

Another application of peptide conjugation is the production of polyclonal antisera.

reaction may be determined by measuring the incorporation of radiolabeled peptide. Unreacted glutaraldehyde and peptide may be separated by dialysis, and the conjugate may be use to raise polyclonal antisera in rabbits, sheep, goats or other animals.

Kringle 5 peptide fragments conjugated to a carrier molecule such as BSA may be combined with an adjuvant n-dxture, emulsified and injected subcutaneously at multiple sites. . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.45

5.66

STN INTERNATIONAL LOGOFF AT 12:26:45 ON 15 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:21:03 ON 15 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:21:11 ON 15 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6

DICTIONARY FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*

\*

\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*

\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s AFSRISSGTG/SQEP
      1 AFSRISSGTG/SQEP
      164195 SQL=10
L1      1 AFSRISSGTG/SQEP
      (AFSRISSGTG/SQEP AND SQL=10)
```

```
=> s AFSRISSGTG/SQSP
L2      111 AFSRISSGTG/SQSP
```

```
=> s 12 and SQL=<100
      9236353 SQL=<100
L3      1 L2 AND SQL=<100
```

```
=> s 12 and SQL=<200
      12730220 SQL=<200
L4      1 L2 AND SQL=<200
```

```
=> s 12 and SQL=<500
      30793008 SQL=<500
L5      1 L2 AND SQL=<500
```

```
=> s 12 and SQL=<700
      45199475 SQL=<700
L6      22 L2 AND SQL=<700
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.86	56.07

FILE 'CAPLUS' ENTERED AT 16:23:04 ON 15 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 14 May 2006 (20060514/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 16:21:03 ON 15 MAY 2006)

FILE 'REGISTRY' ENTERED AT 16:21:11 ON 15 MAY 2006

```
L1      1 S AFSRISSGTG/SQEP
L2      111 S AFSRISSGTG/SQSP
```

L3 1 S L2 AND SQL=<100  
L4 1 S L2 AND SQL=<200  
L5 1 S L2 AND SQL=<500  
L6 22 S L2 AND SQL=<700

FILE 'CAPLUS' ENTERED AT 16:23:04 ON 15 MAY 2006

=> s 11

L7 1 L1

=> d ibib

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1996 CAPLUS

DOCUMENT NUMBER: 142:87715

TITLE: Protein and cDNA sequences of a novel human  
calcium-activated chloride channel protein CLCA2 and  
their use in anti-metastatic therapy

INVENTOR(S): Pauli, Bendicht U.; Elble, Randolph C.; Gruber, Achim  
D.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S.  
Ser. No. 55,412.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265859	A1	20041230	US 2004-779949	20040217
US 6309857	B1	20011030	US 1998-193562	19981117
US 2003059861	A1	20030327	US 2001-55412	20011029
US 6692939	B2	20040217		
PRIORITY APPLN. INFO.:			US 1997-65922P	P 19971117
			US 1998-193562	A3 19981117
			US 2001-55412	A2 20011029
			US 1998-193561	A3 19981117

=> s 16

L8 22 L6

=> s 18 not py>2002

3842052 PY>2002

L9 0 L8 NOT PY>2002

=> s 18 not py>2003

2772810 PY>2003

L10 0 L8 NOT PY>2003

=> s 18 not py>2005

438950 PY>2005

L11 19 L8 NOT PY>2005

=> s 18 not py>2004

1637115 PY>2004

L12 6 L8 NOT PY>2004

=> d ibib 1-6

L12 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1996 CAPLUS

DOCUMENT NUMBER: 142:87715

TITLE: Protein and cDNA sequences of a novel human calcium-activated chloride channel protein CLCA2 and their use in anti-metastatic therapy

INVENTOR(S): Pauli, Bendicht U.; Elble, Randolph C.; Gruber, Achim D.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 55,412.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265859	A1	20041230	US 2004-779949	20040217
US 6309857	B1	20011030	US 1998-193562	19981117
US 2003059861	A1	20030327	US 2001-55412	20011029
US 6692939	B2	20040217		

PRIORITY APPLN. INFO.: US 1997-65922P P 19971117  
US 1998-193562 A3 19981117  
US 2001-55412 A2 20011029  
US 1998-193561 A3 19981117

L12 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:956980 CAPLUS

DOCUMENT NUMBER: 141:406785

TITLE: Polymorphisms in known genes associated with human disease and methods of their detection and uses

INVENTOR(S): Venter, J. Craig; Zhang, Jinghui N.; Liu, Xiangjun; Rowe, William; Cravchik, Anibal; Kalush, Francis; Naik, Ashwinikumar; Subramanian, Gangadharan; Woodage, Trevor

PATENT ASSIGNEE(S): Applera Corporation, USA

SOURCE: U.S., 24 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6812339 B1		20041102	US 2001-XA949016	20010910

PRIORITY APPLN. INFO.: US 2000-2000/PV23149U 20000908  
US 2000-2000/PV23776U 20001003  
US 2000-2000/PV24175U 20001020  
US 2001-2001/949016 20010910

L12 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:589232 CAPLUS

DOCUMENT NUMBER: 141:139147

TITLE: Genes involved in immune related responses observed with asthma, and therapeutic uses in treating airway hyperresponsiveness and/or bronchoalveolar manifestations of asthma

INVENTOR(S): Groot, Pieter Cornelis; Van Bergenhenegouwen, Bram Jeroen; Van Oosterhout, Antonius Josephus Maria

PATENT ASSIGNEE(S): Universiteit Utrecht, Neth.

SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 369,214.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142891	A1	20040722	US 2003-677856	20031002
WO 2002014366	A2	20020221	WO 2001-NL610	20010816
WO 2002014366	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232037	A1	20031218	US 2003-369214	20030215
PRIORITY APPLN. INFO.:				
			WO 2001-NL610	A1 20010816
			US 2003-369214	A2 20030215
			EP 2000-202867	A 20000816

L12 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:10236 CAPLUS

DOCUMENT NUMBER: 136:101081

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.; Mcneill, Patricia D.; Fanger, Neil; Retter, Marc W.; Marnerakis, Margarita; Fanger, Gary Richard; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham, David W.

PATENT ASSIGNEE(S): Corixa Corp., USA

SOURCE: 374 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
AU 2001073149	A5	20020108	AU 2001-73149	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513615	T2	20040513	JP 2002-504957	20010628
PRIORITY APPLN. INFO.:				
			US 2000-606421	A 20000628
			US 2000-630940	A 20000802

US 2000-643597	A	20000821
US 2000-662786	A	20000915
US 2000-685696	A	20001009
US 2000-735705	A	20001212
US 2001-850716	A	20010507
US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
WO 1999-US5798	A1	19990317
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
WO 2001-US21065	W	20010628

L12 ANSWER 5 OF 6 . CAPLUS COPYRIGHT 2006 ACS on STN .

ACCESSION NUMBER: 2000:742121 CAPLUS

DOCUMENT NUMBER: 133:308983

TITLE: Compounds and methods for therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liqun

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061612	A2	20001019	WO 2000-US8896	20000403
WO 2000061612	A3	20010426		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
CA 2369578	AA	20001019	CA 2000-2369578	20000403
EP 1169347	A2	20020109	EP 2000-920102	20000403
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000009505	A	20020611	BR 2000-9505	20000403
JP 2002543769	T2	20021224	JP 2000-611554	20000403
NZ 514818	A	20040430	NZ 2000-514818	20000403
PRIORITY APPLN. INFO.:			US 1999-285479	A 19990402
			US 1999-466396	A 19991217
			US 1999-476496	A 19991230
			US 2000-480884	A 20000110
			US 2000-510376	A 20000222
			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	A1 19990317
			WO 2000-US8896	W 20000403

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:614132 CAPLUS  
DOCUMENT NUMBER: 131:253353  
TITLE: Tumor-specific polypeptide-encoding nucleic acids and  
methods for therapy and diagnosis of lung cancer  
INVENTOR(S): Reed, Steven G.; Wang, Tongtong  
PATENT ASSIGNEE(S): Corixa Corporation, USA  
SOURCE: PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 22  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6210883	B1	20010403	US 1998-40984	19980318
US 6312695	B1	20011106	US 1998-123912	19980727
CA 2323093	AA	19990923	CA 1999-2323093	19990317
AU 9930949	A1	19991011	AU 1999-30949	19990317
BR 9908823	A	20001121	BR 1999-8823	19990317
EP 1064372	A2	20010103	EP 1999-912607	19990317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002533056	T2	20021008	JP 2000-536857	19990317
NZ 506699	A	20031219	NZ 1999-506699	19990317
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
NO 2000004631	A	20001115	NO 2000-4631	20000915
PRIORITY APPLN. INFO.:			US 1998-40802	A 19980318
			US 1998-40984	A 19980318
			US 1998-123912	A 19980727
			US 1998-123933	A 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	W 19990317
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404

=> d ibib hitstr 5-6

L12 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:742121 CAPLUS  
DOCUMENT NUMBER: 133:308983  
TITLE: Compounds and methods for therapy and diagnosis of

INVENTOR(S): lung cancer  
 PATENT ASSIGNEE(S): Wang, Tongtong; Fan, Liqun  
 SOURCE: Corixa Corporation, USA  
 PCT Int. Appl., 261 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 22  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061612	A2	20001019	WO 2000-US8896	20000403
WO 2000061612	A3	20010426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
CA 2369578	AA	20001019	CA 2000-2369578	20000403
EP 1169347	A2	20020109	EP 2000-920102	20000403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009505	A	20020611	BR 2000-9505	20000403
JP 2002543769	T2	20021224	JP 2000-611554	20000403
NZ 514818	A	20040430	NZ 2000-514818	20000403
PRIORITY APPLN. INFO.:				
			US 1999-285479	A 19990402
			US 1999-466396	A 19991217
			US 1999-476496	A 19991230
			US 2000-480884	A 20000110
			US 2000-510376	A 20000222
			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	A1 19990317
			WO 2000-US8896	W 20000403
IT 245058-16-6				
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino acid sequence; lung tumor proteins and DNA encoding them for therapy and diagnosis of lung cancer)				
RN 245058-16-6 CAPLUS				
CN Tumor-specific antigen L762P (human isoform 1) (9CI) (CA INDEX NAME)				

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L12 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1999:614132 CAPLUS  
 DOCUMENT NUMBER: 131:253353  
 TITLE: Tumor-specific polypeptide-encoding nucleic acids and  
 methods for therapy and diagnosis of lung cancer  
 INVENTOR(S): Reed, Steven G.; Wang, Tongtong  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6210883	B1	20010403	US 1998-40984	19980318
US 6312695	B1	20011106	US 1998-123912	19980727
CA 2323093	AA	19990923	CA 1999-2323093	19990317
AU 9930949	A1	19991011	AU 1999-30949	19990317
BR 9908823	A	20001121	BR 1999-8823	19990317
EP 1064372	A2	20010103	EP 1999-912607	19990317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002533056	T2	20021008	JP 2000-536857	19990317
NZ 506699	A	20031219	NZ 1999-506699	19990317
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
NO 2000004631	A	20001115	NO 2000-4631	20000915
PRIORITY APPLN. INFO.:				
			US 1998-40802	A 19980318
			US 1998-40984	A 19980318
			US 1998-123912	A 19980727
			US 1998-123933	A 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	W 19990317
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
IT 245058-16-6				
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)				
(amino acid sequence; tumor-specific polypeptide-encoding nucleic acids and methods for therapy and diagnosis of lung cancer)				
RN 245058-16-6	CAPLUS			
CN	Tumor-specific antigen L762P (human isoform 1) (9CI) (CA INDEX NAME)			

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.56	76.63

FILE 'REGISTRY' ENTERED AT 16:25:20 ON 15 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6  
DICTIONARY FILE UPDATES: 14 MAY 2006 HIGHEST RN 884198-07-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> S 245058-16-6/RN

L13 1 245058-16-6/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> D L13 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y  
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 245058-16-6 REGISTRY  
CN Tumor-specific antigen L762P (human isoform 1) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 169: PN: WO0061612 SEQID: 169 claimed protein  
CN PN: WO9947674 SEQID: 169 claimed protein  
CN Protein (human clone L762P-1)  
CN Protein (human lung neoplasm clone L762P-1)  
FS PROTEIN SEQUENCE  
SQL 592

PATENT ANNOTATIONS (PNTE):  
Sequence |Patent  
Source |Reference  
=====+=====

Not Given|WO2000061612  
|claimed  
|SEQID 169  
-----+-----  
|WO9947674  
|claimed  
|SEQID 169

SEQ 1 MTQRSIAGPI CNLKFTVLLV ALSSELPFLG AGVQLQDNGY NGLLIAINPQ  
51 VPENQNLISN IKEMITEASF YLFNATKRRV FFRNIKILIP ATWKANNNSK  
101 IKQESYEKAN VIVTDWYGAG GDDPYTLQYR GCGKEGKYIH FTPNFLLNDN  
151 LTAGYGSRGR VVHVEWAHLR WGVFDEYNND KPFYINGQNO IKVTRCSSDI  
201 TGIFVCEKGP CPQENCIISK LFKEGCTFIY NSTQNATASI MFMQSLSSVV  
251 EFCNASTHNQ EAPNLQNQMC SLRSAWDVIT DSADFHHSFP MNGTELPPPP  
301 TFSLVEAGDK VVCLVLDVSS KMAEADRLLQ LQQAAEFYLM QIVEIHTFVG  
351 IASFDSKGEI RAQLHQINSN DDRKLLVSYL PTTVSAKTDI SICSGLKKGF  
401 EVVEKLNKGA YGSVMILVTS GDDKLLGNCL PTVLSSGSTI HSIALGSSAA  
451 PNLEELSRLT GGLKFFVPDI SNSNSMIDAF SRISSTGDI FQHQIQUEST  
501 GENVKPHHQL KNTVTVDNTV GNDTMFLVTW QASGPPEIIL FDPDGRKYYT  
551 NNFITNLTR TASLWIPGTA KPGHWYTYLM CFHHAKLLTW KL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PRP  
(Properties); USES (Uses)

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=>

<-----User Break----->

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> D L13 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y  
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 245058-16-6 REGISTRY

CN Tumor-specific antigen L762P (human isoform 1) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 169: PN: WO0061612 SEQID: 169 claimed protein

CN PN: WO9947674 SEQID: 169 claimed protein

CN Protein (human clone L762P-1)

CN Protein (human lung neoplasm clone L762P-1)

FS PROTEIN SEQUENCE

SQL 592

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2000061612
	claimed
	SEQID 169
	WO9947674
	claimed
	SEQID 169

```

SEQ      1 MTQRSIAGPI CNLKFTVLLV ALSSELPFLG AGVQLQDNGY NGLLIAINPQ
      51 VPENQNLI SN IKEMITEASF YLFNATKRRV FFRNIKILIP ATWKANNNSK
     101 IKQESYEKAN VIVTDWYGAH GDDPYTLQYR GCGKEGKYIH FTPNFLLNDN
     151 LTAGYGSRGR VVHEWAHLR WGVFDEYNND KPFYINGQNO IKVTRCSSDI
     201 TGIFVCEKGP CPQENCIISK LFKEGCTFIY NSTQNATASI MFMQSLSSVV
     251 EFCNASTHNQ EAPNLQNMCM SLRSAWDVIT DSADFHHSP MNGTELPPPP
     301 TFSLVEAGDK VVCLVLDVSS KMAEADRLQ LQQAEEFYLM QIVEIHTFVG
     351 IASFDSKGEI RAQLHQINSN DDRKLLVSYL PTTVSAKTDI SICSGLKKGF
     401 EVVEKLNKGA YGSVMILVTS GDDKLLGNCL PTVLSSGSTI HSIALGSSAA
     451 PNLEELSRLT GGLKFFVPDI SNSNSMIDAF SRISSGTGDI FQQHIQLEST
     501 GENVKPHHQL KNTVTVDNTV GNDTMFLVTW QASGPPEIIL FDPDGRKYYT
     551 NNFITNLTFR TASLWIPGTA KPGHWYTLN CFHHAKLLTW KL
  
```

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

```

MF      Unspecified
CI      MAN
SR      CA
LC      STN Files:  CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA   Caplus document type:  Patent
RL.P    Roles from patents:  BIOL (Biological study); OCCU (Occurrence); PRP
        (Properties); USES (Uses)
        2 REFERENCES IN FILE CA (1907 TO DATE)
        2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
  
```

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=>

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.92	91.55

STN INTERNATIONAL LOGOFF AT 16:28:11 ON 15 MAY 2006



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would  
like to better understand what you find useful. Please take

approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:04:45 ON 16 MAY 2006

=> file reg

---Logging off of STN---

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:04:56 ON 16 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0  
DICTIONARY FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Executing the logoff script...

=> LOG Y

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005..  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:05:34 ON 16 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:06:02 ON 16 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

DICTIONARY FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s RLLDTNRPLLPY/SESP

'SESP' IS NOT A VALID FIELD CODE

L1 0 RLLDTNRPLLPY/SESP

=> s RLLDTNRPLLPY/SQSP

L2

1 RLLDTNRPLLPY/SQSP

=&gt; file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

28.89

29.10

FILE 'CAPLUS' ENTERED AT 15:06:25 ON 16 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2006 VOL 144 ISS 21

FILE LAST UPDATED: 15 May 2006 (20060515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=&gt; s l1

L3 0 L1

=&gt; s l2

L4 2 L2

=&gt; d ibib 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:34642 CAPLUS

DOCUMENT NUMBER: 142:120467

TITLE: Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof

INVENTOR(S): Wu, Han-chung; Lin, Chin-tarng; Lee, Tong-young

PATENT ASSIGNEE(S): Taiwan

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005010036	A1	20050113	US 2004-796892	20040309
PRIORITY APPLN. INFO.:			TW 2003-92117944	A 20030701

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:913617 CAPLUS

DOCUMENT NUMBER: 142:48706

TITLE: A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery

AUTHOR(S): Lee, Tong-Young; Wu, Han-Chung; Tseng, Yun-Long; Lin, Chin-Tarng

CORPORATE SOURCE: Institute of Pathology, College of Medicine, National  
Taiwan University, Taipei, Taiwan  
SOURCE: Cancer Research (2004), 64(21), 8002-8008  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	4.12	33.22

FILE 'REGISTRY' ENTERED AT 15:08:35 ON 16 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0  
DICTIONARY FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s LPY/SQSP
L5      159291 LPY/SQSP

=> s 15 and SQL=<100
      9236353 SQL=<100
L6      9300 L5 AND SQL=<100

=> s 16 and SQL=<=10
      622539 SQL=<=10
L7      656 L6 AND SQL=<=10

=> file caplus
```

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.29

72.51

FILE 'CAPLUS' ENTERED AT 15:10:06 ON 16 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2006 VOL 144 ISS 21

FILE LAST UPDATED: 15 May 2006 (20060515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17

L8 521 L7

=> s cancer? or tumor? or neoplas?

292597 CANCER?

427416 TUMOR?

448874 NEOPLAS?

L9 707975 CANCER? OR TUMOR? OR NEOPLAS?

=> s 18 and 19

L10 218 L8 AND L9

=> s nasopharyngeal

L11 3311 NASOPHARYNGEAL

=> s l11 and l10

L12 0 L11 AND L10

=> s l11 and l8

L13 0 L11 AND L8

=> s 18 (1) 19

L14 91 L8 (L) L9

=> s l14 not py>2002

3846061 PY>2002

L15 30 L14 NOT PY>2002

=> s l14 not py>2003

2776838 PY>2003

L16 34 L14 NOT PY>2003

=> s l16 and lipsom?

75 LIPSOM?

L17 0 L16 AND LIPSOM?

=> s l16 and liposom?

50022 LIPOSOM?

L18 1 L16 AND LIPOSOM?

=> d ibib

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:12285 CAPLUS  
DOCUMENT NUMBER: 134:99563  
TITLE: HLA binding peptides and their uses  
INVENTOR(S): Sette, Alessandro; Sidney, John; Southwood, Scott  
PATENT ASSIGNEE(S): Epimmune Inc., USA  
SOURCE: PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000225	A1	20010104	WO 2000-US17842	20000628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2370413	AA	20010104	CA 2000-2370413	20000628
EP 1189624	A1	20020327	EP 2000-944976	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003535024	T2	20031125	JP 2001-505934	20000628
PRIORITY APPLN. INFO.:			US 1999-141422P	P 19990629
			WO 2000-US17842	W 20000628
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d kwic

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

IT Drug delivery systems  
(liposomes; HLA binding peptides for treating viral diseases and cancers)

IT 141677-18-1	151808-62-7	151808-66-1	151819-94-2	160213-58-1
160213-61-6	160213-63-8	160214-77-7	160544-00-3	172518-49-9
179760-94-2	196514-98-4	196515-02-3	196515-04-5	197089-71-7
201935-51-5	201935-53-7	201935-54-8	201935-55-9	201935-57-1
201935-58-2	201935-60-6	201935-61-7	201935-63-9	201935-66-2
201935-67-3	201935-68-4	201935-69-5	201935-76-4	231284-80-3
250728-11-1	250728-57-5	252936-91-7	252936-92-8	260987-44-8
318272-47-8	318272-48-9	318272-49-0	318272-52-5	318272-54-7
318272-56-9	318272-58-1	318272-60-5	318272-63-8	318272-65-0
318272-67-2	318272-69-4	318272-71-8	318272-73-0	318272-75-2
318272-77-4	318272-79-6	318272-80-9	318272-83-2	318272-85-4
318272-88-7	318272-90-1	318272-92-3	318272-93-4	
318272-94-5	318272-95-6	318272-96-7	318272-97-8	318272-98-9
318272-99-0	318273-00-6	318273-01-7	318273-02-8	318273-03-9
318273-04-0	318273-05-1	318273-06-2	318273-07-3	318273-08-4
318273-09-5	318273-10-8	318273-11-9	318273-12-0	318273-13-1
318273-14-2	318273-15-3	318273-16-4	318273-17-5	318273-18-6
318273-19-7	318273-20-0	318273-21-1	318273-22-2	318273-23-3



318273-24-4	318273-25-5	318273-26-6	318273-27-7	318273-28-8
318273-29-9	318273-30-2	318273-31-3	318273-32-4	318273-33-5
318273-34-6	318273-35-7	318273-36-8	318273-37-9	318273-38-0
318273-39-1	318273-40-4	318273-41-5	318273-42-6	318273-43-7
318273-44-8	318273-45-9	318273-46-0	318273-47-1	318273-48-2
318273-49-3	318273-50-6	318273-51-7	318273-52-8	318273-53-9
318273-54-0	318273-55-1	318273-56-2	318273-57-3	318273-58-4
318273-59-5	318273-60-8	318273-61-9	318273-62-0	318273-63-1
318273-64-2	318273-65-3	318273-66-4	318273-67-5	318273-68-6
318273-69-7	318273-70-0	318273-71-1	318273-72-2	318273-73-3
318273-74-4	318273-75-5	318273-76-6	318273-77-7	318273-78-8
318273-79-9	318273-80-2	318273-81-3	318273-82-4	318273-83-5
318273-84-6	318273-85-7	318273-86-8	318273-87-9	318273-88-0
318273-89-1	318273-90-4	318273-91-5	318273-92-6	318273-93-7
318273-94-8	318273-95-9	318273-96-0	318273-97-1	318273-98-2
318273-99-3	318274-00-9	318274-01-0	318274-02-1	318274-03-2
318274-04-3	318274-05-4	318274-06-5	318274-07-6	318274-08-7
318274-09-8	318274-10-1	318274-11-2	318274-13-4	318274-15-6
318274-17-8	318274-19-0	318274-21-4	318274-23-6	318274-25-8
318274-27-0	318274-29-2	318274-31-6	318274-33-8	318274-36-1
318274-39-4	318274-42-9	318274-43-0	318274-45-2	318274-47-4
318274-49-6	318274-52-1	318274-54-3	318274-56-5	318274-58-7
318274-60-1	318274-62-3	318274-64-5	318274-66-7	318274-68-9
318274-70-3	318274-72-5	318274-73-6	318274-74-7	318274-75-8
318274-76-9	318274-77-0	318274-78-1	318274-79-2	318274-80-5
318274-81-6	318274-82-7	318274-83-8	318274-84-9	318274-85-0
318274-86-1	318274-87-2	318274-88-3	318274-89-4	318274-90-7
318274-91-8	318274-92-9	318274-93-0	318274-94-1	318274-95-2
318274-96-3	318274-97-4	318274-98-5	318274-99-6	318275-00-2

RL: ANT (Analyte); PRP (Properties); THU (Therapeutic use); ANST  
(Analytical study); BIOL (Biological study); USES (Uses)  
(HLA binding peptides for treating viral diseases and cancers  
)

IT	318470-39-2	318470-40-5	318470-41-6	318470-42-7	318470-43-8
	318470-44-9	318470-45-0	318470-46-1	318470-47-2	318470-48-3
	318470-49-4	318470-50-7	318470-51-8	318470-52-9	318470-53-0
	318470-54-1	318470-55-2	318470-56-3	318470-57-4	318470-58-5
	318470-59-6	318470-60-9	318470-61-0	318470-62-1	318470-63-2
	318470-64-3	318470-65-4	318470-66-5	318470-67-6	318470-68-7
	318470-69-8	318470-70-1	318470-71-2	318470-72-3	318470-73-4
	318470-74-5	318470-75-6	318470-76-7	318470-77-8	318470-78-9
	318470-79-0	318470-80-3	318470-81-4	318470-82-5	318470-83-6
	318470-84-7	318470-85-8	318470-86-9	318470-87-0	
	318470-88-1	318470-89-2	318470-90-5	318470-91-6	318470-92-7
	318470-93-8	318470-94-9	318470-95-0	318470-96-1	318470-97-2
	318470-98-3	318470-99-4	318471-00-0	318471-01-1	318471-02-2
	318471-03-3	318510-96-2			

RL: ANT (Analyte); PRP (Properties); THU (Therapeutic use); ANST  
(Analytical study); BIOL (Biological study); USES (Uses)  
(HLA binding peptides for treating viral diseases and cancers  
)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	19.37	91.88

FILE 'REGISTRY' ENTERED AT 15:13:18 ON 16 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0  
DICTIONARY FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> S 318470-87-0/RN

L19 1 318470-87-0/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> D L19 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y  
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 318470-87-0 REGISTRY  
CN L-Tyrosine, L-leucyl-L-leucyl-L-seryl-L-threonyl-L-asparaginyll-L-leucyl-L-  
prolyl- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 114: PN: W00100225 TABLE: 9 claimed sequence  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 8

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+	
Not Given	W02001000225
	claimed
	TABLE 9

SEQ 1 LLSTNLPY

MF C43 H69 N9 O13  
SR CA  
LC STN Files: CA, CAPLUS; TOXCENTER  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
PRP (Properties); USES (Uses)

Absolute stereochemistry.

/ Structure 2 in file .gra /

/ Structure 3 in file .gra /

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=>

=> d his

(FILE 'HOME' ENTERED AT 15:05:34 ON 16 MAY 2006)

FILE 'REGISTRY' ENTERED AT 15:06:02 ON 16 MAY 2006

L1 0 S RLLDTNRPLL PY/SESP  
L2 1 S RLLDTNRPLL PY/SQSP

FILE 'CAPLUS' ENTERED AT 15:06:25 ON 16 MAY 2006

L3 0 S L1  
L4 2 S L2

FILE 'REGISTRY' ENTERED AT 15:08:35 ON 16 MAY 2006

L5 159291 S LPY/SQSP  
L6 9300 S L5 AND SQL<=100  
L7 656 S L6 AND SQL<=10

FILE 'CAPLUS' ENTERED AT 15:10:06 ON 16 MAY 2006

L8 521 S L7  
L9 707975 S CANCER? OR TUMOR? OR NEOPLAS?  
L10 218 S L8 AND L9  
L11 3311 S NASOPHARYNGEAL  
L12 0 S L11 AND L10  
L13 0 S L11 AND L8  
L14 91 S L8 (L) L9  
L15 30 S L14 NOT PY>2002  
L16 34 S L14 NOT PY>2003  
L17 0 S L16 AND LIPSOM?  
L18 1 S L16 AND LIPOSOM?

FILE 'REGISTRY' ENTERED AT 15:13:18 ON 16 MAY 2006

L19 1 S 318470-87-0/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.12	100.00

STN INTERNATIONAL LOGOFF AT 15:15:43 ON 16 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes..  
NEWS 9 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 10 MAR 22 EMBASE is now updated on a daily basis  
NEWS 11 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 12 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 13 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 14 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 15 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 16 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 17 MAY 10 CA/CaPlus enhanced with 1900-1906 U.S. patent records  
NEWS 18 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:34:26 ON 16 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:34:39 ON 16 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

DICTIONARY FILE UPDATES: 15 MAY 2006 HIGHEST RN 884382-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*

\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*

\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s LPY/SQSP and SQL<=15
      1060 LPY/SQSP
      1417454 SQL<=15
L1      1060 LPY/SQSP AND SQL<=15
```

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          34.09      34.30
```

FILE 'CAPLUS' ENTERED AT 15:35:33 ON 16 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 15 May 2006 (20060515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l1
L2      713 L1

=> s tumor? or cancer? or neoplas?
      427416 TUMOR?
      292597 CANCER?
      448874 NEOPLAS?
L3      707975 TUMOR? OR CANCER? OR NEOPLAS?

=> s l2 (L) l3
L4      103 L2 (L) L3

=> s l4 and liposom?
      50022 LIPOSOM?
L5      8 L4 AND LIPOSOM?

=> s l5 not py>2003
      2776838 PY>2003
L6      1 L5 NOT PY>2003
```

=> d ibib

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2001:12285 CAPLUS  
DOCUMENT NUMBER: 134:99563  
TITLE: HLA binding peptides and their uses  
INVENTOR(S): Sette, Alessandro; Sidney, John; Southwood, Scott  
PATENT ASSIGNEE(S): Epimmune Inc., USA  
SOURCE: PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000225	A1	20010104	WO 2000-US17842	20000628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2370413	AA	20010104	CA 2000-2370413	20000628
EP 1189624	A1	20020327	EP 2000-944976	20000628
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003535024	T2	20031125	JP 2001-505934	20000628
PRIORITY APPLN. INFO.:			US 1999-141422P	P 19990629
			WO 2000-US17842	W 20000628
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=> d his

(FILE 'HOME' ENTERED AT 15:34:26 ON 16 MAY 2006)

FILE 'REGISTRY' ENTERED AT 15:34:39 ON 16 MAY 2006

L1 1060 S LPY/SQSP AND SQL<=15

FILE 'CAPLUS' ENTERED AT 15:35:33 ON 16 MAY 2006

L2 713 S L1

L3 707975 S TUMOR? OR CANCER? OR NEOPLAS?

L4 103 S L2 (L) L3

L5 8 S L4 AND LIPOSOM?

L6 1 S L5 NOT PY>2003

=> s nasopharyngeal

L7 3311 NASOPHARYNGEAL

=> s l7 and l2

L8 3 L7 AND L2

=> d ibib 1-3

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:149841 CAPLUS  
DOCUMENT NUMBER: 144:186074  
TITLE: Genome sequence of human coronavirus HKU1 causing

respiratory tract infection and its uses in diagnosis and treatment of infections

INVENTOR(S): Yuen, Kwok Yung; Woo, Chiu Yat Patrick; Lau, Kar Pui Susanna; Chan, Kwok Hung

PATENT ASSIGNEE(S): Peop. Rep. China

SOURCE: U.S. Pat. Appl. Publ., 231 pp., Cont.-in-part of U.S. Ser. No. 895,064.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006034853	A1	20060216	US 2005-129741	20050516
US 2006018923	A1	20060126	US 2004-895064	20040721
WO 2006007795	A1	20060126	WO 2005-CN1088	20050720

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-895064 A2 20040721  
US 2005-129741 A 20050516

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:34642 CAPLUS

DOCUMENT NUMBER: 142:120467

TITLE: Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof

INVENTOR(S): Wu, Han-chung; Lin, Chin-tarng; Lee, Tong-young

PATENT ASSIGNEE(S): Taiwan

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005010036	A1	20050113	US 2004-796892	20040309

PRIORITY APPLN. INFO.: TW 2003-92117944 A 20030701

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:913617 CAPLUS

DOCUMENT NUMBER: 142:48706

TITLE: A Novel Peptide Specifically Binding to Nasopharyngeal Carcinoma For Targeted Drug Delivery

AUTHOR(S): Lee, Tong-Young; Wu, Han-Chung; Tseng, Yun-Long; Lin, Chin-Tarng

CORPORATE SOURCE: Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan

SOURCE: Cancer Research (2004), 64(21), 8002-8008

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research



DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 1

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 AB . . . belongs to the order Nidovirales of the family Coronaviridae,  
 being a single-stranded RNA virus of pos. polarity. Further study on  
 nasopharyngeal aspirates from patients with community-acquired  
 pneumonia has revealed that there are two genotypes, genotype A and  
 genotype B, for this.

IT 875064-83-8 875064-84-9 875064-85-0 875064-86-1 875064-87-2  
 875064-88-3 875064-89-4 875064-90-7 875064-91-8 875064-92-9  
 875064-93-0 875064-94-1 875064-95-2 875064-96-3 875064-97-4  
 875064-98-5 875064-99-6 875065-00-2 875065-01-3 875065-02-4  
 875065-03-5 875065-04-6 875065-05-7 875065-06-8 875065-07-9  
 875065-08-0 875065-09-1 875065-12-6 875065-15-9  
 875065-18-2 875065-21-7 875065-24-0 875065-27-3 875065-30-8  
 875065-33-1 875065-36-4 875065-39-7 875065-40-0 875065-41-1  
 875065-42-2 875065-43-3 875065-44-4 875065-45-5 875065-46-6  
 875065-47-7 875065-48-8 875065-49-9 875065-50-2 875065-51-3  
 875065-52-4 875065-53-5 875065-54-6 875065-55-7 875065-56-8  
 875065-57-9 875065-58-0 875065-59-1 875065-60-4 875065-61-5  
 875065-62-6 875065-63-7 875065-64-8 875065-65-9 875065-66-0  
 875065-67-1 875065-68-2 875065-69-3 875065-70-6 875065-71-7  
 875065-72-8 875065-73-9 875065-74-0 875065-75-1 875065-76-2  
 875065-77-3 875065-78-4 875065-79-5 875065-80-8 875065-81-9  
 875065-82-0 875065-83-1 875065-84-2 875065-85-3 875065-86-4  
 875065-87-5 875065-88-6 875065-89-7 875065-90-0 875065-91-1  
 875065-92-2 875065-93-3 875065-94-4 875065-95-5 875065-96-6  
 875065-97-7 875065-98-8 875065-99-9 875066-00-5 875066-01-6  
 875066-02-7 875066-03-8 875066-04-9 875066-05-0 875066-06-1  
 875066-07-2 875066-08-3 875066-09-4 875066-10-7 875066-11-8  
 875066-12-9 875066-13-0 875066-14-1 875066-15-2 875066-16-3  
 875066-17-4 875066-18-5 875066-19-6 875066-20-9 875066-21-0  
 875066-22-1 875066-23-2 875066-25-4 875066-28-7 875066-29-8  
 875066-30-1 875066-31-2 875066-32-3 875066-33-4 875066-34-5  
 875066-35-6 875066-36-7 875066-37-8 875066-38-9 875066-39-0  
 875066-40-3 875066-41-4 875066-42-5 875066-43-6 875066-44-7  
 875066-46-9 875066-48-1 875066-50-5 875066-52-7 875066-54-9  
 875066-56-1 875066-57-2 875066-59-4 875066-61-8 875066-63-0  
 875066-65-2 875066-66-3 875066-68-5 875066-70-9 875066-72-1  
 875066-74-3 875066-75-4 875066-77-6 875066-79-8 875066-80-1  
 875066-81-2 875066-82-3 875066-83-4 875066-84-5 875066-85-6  
 875066-86-7 875066-87-8 875066-88-9 875066-89-0 875066-90-3  
 875066-91-4 875066-92-5 875066-93-6 875066-94-7 875066-95-8  
 875066-96-9 875066-97-0 875066-98-1 875066-99-2 875067-00-8  
 875067-01-9 875067-02-0 875067-03-1 875067-04-2 875067-05-3  
 875067-06-4 875067-07-5 875067-08-6 875067-09-7 875067-10-0  
 875067-11-1 875067-12-2 875067-13-3 875067-14-4 875067-15-5  
 875067-16-6 875067-17-7 875067-18-8 875067-19-9 875067-20-2  
 875067-21-3 875067-22-4 875067-23-5 875067-24-6 875067-25-7  
 875067-26-8 875067-27-9 875067-28-0 875067-29-1 875067-30-4  
 875067-31-5 875067-32-6 875067-33-7 875067-34-8 875067-35-9  
 875067-36-0 875067-37-1 875067-38-2 875067-39-3 875067-40-6  
 875067-41-7 875067-42-8 875067-43-9 875067-44-0 875067-45-1  
 875067-46-2 875067-47-3 875067-48-4 875067-49-5 875067-50-8  
 875067-51-9 875067-52-0 875067-53-1 875067-54-2 875067-55-3  
 875067-56-4 875067-57-5 875067-58-6 875067-59-7 875067-60-0

RL: PRP (Properties)

(unclaimed protein sequence; genome sequence of human coronavirus HKU1  
 causing respiratory tract infection and its uses in diagnosis and

	treatment of infections)				
IT	875070-00-1	875070-01-2	875070-02-3	875070-03-4	875070-04-5
	875070-05-6	875070-06-7	875070-07-8	875070-08-9	875070-09-0
	875070-10-3	875070-11-4	875070-12-5	875070-13-6	875070-14-7
	875070-15-8	875070-16-9	875070-17-0	875070-18-1	875070-19-2
	875070-20-5	875070-21-6	875070-22-7	875070-23-8	875070-24-9
	875070-25-0	875070-26-1	875070-27-2	875070-28-3	875070-29-4
	875070-30-7	875070-31-8	875070-32-9	875070-33-0	875070-34-1
	875070-35-2	875070-36-3	875070-37-4	875070-38-5	875070-39-6
	875070-40-9	875070-41-0	875070-42-1	875070-43-2	875070-44-3
	875070-45-4	875070-46-5	875070-47-6	875070-48-7	875070-49-8
	875070-50-1	875070-51-2	875070-52-3	875070-53-4	875070-54-5
	875070-55-6	875070-56-7	875070-57-8	875070-58-9	875070-59-0
	875070-60-3	875070-61-4	875070-62-5	875070-63-6	875070-64-7
	875070-65-8	875070-66-9	875070-67-0	875070-68-1	875070-69-2
	875070-70-5	875070-71-6	875070-72-7	875070-73-8	875070-74-9
	875070-75-0	875070-76-1	875070-77-2	875070-78-3	875070-79-4
	875070-80-7	875070-81-8	875070-82-9	875070-83-0	875070-84-1
	875070-85-2	875070-86-3	875070-87-4	875070-88-5	
	875070-89-6	875070-90-9	875070-91-0	875070-92-1	875070-93-2
	875070-94-3	875070-95-4	875070-96-5	875070-97-6	875070-98-7
	875070-99-8	875071-00-4	875071-01-5	875071-02-6	875071-03-7
	875071-04-8	875071-05-9	875071-06-0	875071-07-1	875071-08-2
	875071-09-3	875071-10-6	875071-11-7	875071-12-8	875071-13-9
	875071-14-0	875071-15-1	875071-16-2	875071-17-3	875071-18-4
	875071-19-5	875071-20-8	875071-21-9	875071-22-0	875071-23-1
	875071-24-2	875071-25-3	875071-26-4	875071-27-5	875071-28-6
	875071-29-7	875071-30-0	875071-31-1	875071-32-2	875071-33-3
	875071-34-4	875071-35-5	875071-36-6	875071-37-7	875071-38-8
	875071-39-9	875071-40-2	875071-41-3	875071-42-4	875071-43-5
	875071-44-6	875071-45-7	875071-46-8	875071-47-9	875071-48-0
	875071-49-1	875071-50-4	875071-51-5	875071-52-6	875071-53-7
	875071-54-8	875071-55-9	875071-56-0	875071-57-1	875071-58-2
	875071-59-3	875071-60-6	875071-61-7	875071-62-8	875071-63-9
	875071-64-0	875071-65-1	875071-66-2	875071-67-3	875071-68-4
	875071-69-5	875071-70-8	875071-71-9	875071-72-0	875071-73-1
	875071-74-2	875071-75-3	875071-76-4	875071-77-5	875071-78-6
	875071-79-7	875071-80-0	875071-81-1	875071-82-2	875071-83-3
	875071-84-4	875071-85-5	875071-86-6	875071-87-7	875071-89-9
	875071-90-2	875071-91-3	875071-92-4	875071-93-5	875071-94-6
	875071-95-7	875071-96-8	875071-98-0	875071-99-1	875072-00-7
	875072-01-8	875072-03-0	875072-04-1	875072-05-2	875072-07-4
	875072-09-6	875072-10-9	875072-11-0	875072-12-1	875072-13-2
	875072-14-3	875072-15-4	875072-16-5	875072-17-6	875072-18-7
	875072-19-8	875072-20-1	875072-21-2	875072-22-3	875072-23-4
	875072-24-5	875072-25-6	875072-26-7	875072-27-8	875072-28-9
	875072-29-0	875072-30-3	875072-31-4	875072-32-5	875072-33-6
	875072-34-7	875072-35-8	875072-36-9	875072-37-0	875072-38-1
	875072-39-2	875072-40-5	875072-41-6	875072-42-7	875072-43-8

RL: PRP (Properties)

(unclaimed protein sequence; genome sequence of human coronavirus HKU1  
causing respiratory tract infection and its uses in diagnosis and  
treatment of infections)

IT	875080-19-6	875080-21-0	875080-23-2	875080-25-4	875080-27-6
	875080-29-8	875080-31-2	875080-33-4	875080-35-6	875080-37-8
	875080-39-0	875080-41-4	875080-43-6	875080-45-8	875080-47-0
	875080-49-2	875080-51-6	875080-53-8	875080-55-0	875080-57-2
	875080-59-4	875080-61-8	875080-63-0	875080-65-2	875080-67-4
	875080-69-6	875080-71-0	875080-73-2	875080-75-4	875080-77-6
	875080-79-8	875080-81-2	875080-83-4	875080-85-6	875080-87-8
	875080-89-0	875080-91-4	875080-93-6	875080-95-8	875080-97-0
	875080-99-2	875081-01-9	875081-03-1	875081-05-3	875081-07-5
	875081-09-7	875081-11-1	875081-13-3	875081-16-6	875081-18-8
	875081-20-2	875081-22-4	875081-24-6	875081-26-8	875081-28-0
	875081-30-4	875081-32-6	875081-34-8	875081-36-0	875081-38-2

875081-40-6	875081-42-8	875081-44-0	875081-46-2	875081-48-4
875081-50-8	875081-52-0	875081-54-2	875081-57-5	875081-60-0
875081-62-2	875081-65-5	875081-68-8	875081-71-3	875081-74-6
875081-77-9	875081-80-4	875081-82-6	875081-84-8	875081-86-0
875081-88-2	875081-90-6	875081-92-8	875081-94-0	875081-96-2
875081-98-4	875082-00-1	875082-02-3	875082-04-5	875082-06-7
875082-08-9	875082-10-3	875082-12-5	875082-14-7	875082-16-9
875082-18-1	875082-21-6	875082-24-9	875082-27-2	875082-30-7
875082-32-9	875082-34-1	875082-36-3	875082-38-5	875082-41-0
875082-43-2	875082-45-4	875082-47-6	875082-49-8	875082-51-2
875082-53-4	875082-55-6	875082-57-8	875082-59-0	875082-61-4
875082-63-6	875082-65-8	875082-67-0	875082-69-2	875082-71-6
875082-73-8	875082-75-0	875082-77-2	875082-79-4	875082-82-9
875082-84-1	875082-87-4	875082-89-6	875082-91-0	875082-94-3
875082-96-5	875082-98-7	875083-00-4	875083-02-6	875083-04-8
875083-06-0	875083-08-2	875083-10-6	875083-12-8	875083-14-0
875083-16-2	875083-18-4	875083-20-8	875083-22-0	875083-24-2
875083-26-4	875083-28-6	875083-30-0	875083-33-3	875083-35-5
875083-37-7	875083-39-9	875083-41-3	875083-43-5	875083-45-7
875083-47-9	875083-49-1	875083-51-5	875083-53-7	875083-55-9
875083-57-1	875083-59-3	875083-61-7	875083-63-9	875083-65-1
875083-67-3	875083-69-5	875083-71-9	875083-73-1	875083-75-3
875083-77-5	875083-79-7	875083-81-1	875083-83-3	875083-85-5
875083-87-7	875083-89-9	875083-91-3	875083-93-5	875083-95-7
875083-97-9	875083-99-1	875084-01-8	875084-03-0	875084-05-2
875084-07-4	875084-09-6	875084-11-0	875084-13-2	875084-15-4
875084-17-6	875084-19-8	875084-21-2	875084-23-4	875084-25-6
875084-27-8	875084-29-0	875084-31-4	875084-33-6	875084-35-8
875084-37-0	875084-39-2	875084-41-6	875084-43-8	875084-45-0
875084-47-2	875084-49-4	875084-51-8	875084-54-1	875084-56-3
875084-58-5	875084-60-9	875084-62-1	875084-64-3	875084-66-5
875084-68-7	875084-70-1	875084-72-3	875084-74-5	875084-76-7
875084-78-9	875084-80-3	875084-82-5	875084-84-7	875084-86-9
875084-88-1	875084-90-5	875084-92-7	875084-94-9	875084-96-1
875084-98-3	875085-00-0	875085-02-2	875085-04-4	875085-06-6
875085-08-8	875085-10-2	875085-12-4	875085-14-6	

RL: PRP (Properties)

(unclaimed protein sequence; genome sequence of human coronavirus HKU1 causing respiratory tract infection and its uses in diagnosis and treatment of infections)

IT	875090-47-4	875090-48-5	875090-49-6	875090-50-9	875090-51-0
	875090-52-1	875090-53-2	875090-54-3	875090-55-4	875090-56-5
	875090-57-6	875090-58-7	875090-59-8	875090-60-1	875090-61-2
	875090-62-3	875090-63-4	875090-64-5	875090-65-6	875090-66-7
	875090-67-8	875090-68-9	875090-69-0	875090-70-3	875090-71-4
	875090-72-5	875090-73-6	875090-74-7	875090-75-8	875090-76-9
	875090-77-0	875090-78-1	875090-79-2	875090-80-5	875090-81-6
	875090-82-7	875090-83-8	875090-84-9	875090-85-0	875090-86-1
	875090-87-2	875090-88-3	875090-89-4	875090-90-7	875090-91-8
	875090-92-9	875090-93-0	875090-94-1	875090-95-2	875090-96-3
	875090-97-4	875090-98-5	875090-99-6	875091-00-2	875091-01-3
	875091-02-4	875091-03-5	875091-04-6	875091-05-7	875091-06-8
	875091-07-9	875091-08-0	875091-09-1	875091-10-4	875091-11-5
	875091-12-6	875091-13-7	875091-15-9	875091-17-1	875091-19-3
	875091-21-7	875091-23-9	875091-25-1	875091-27-3	875091-29-5
	875091-31-9	875091-32-0	875091-33-1	875091-34-2	875091-35-3
	875091-36-4	875091-37-5	875091-38-6	875091-39-7	875091-40-0
	875091-41-1	875091-42-2	875091-43-3	875091-44-4	875091-45-5
	875091-46-6	875091-47-7	875091-48-8	875091-49-9	875091-50-2
	875091-51-3	875091-52-4	875091-53-5	875091-54-6	875091-55-7
	875091-56-8	875091-57-9	875091-58-0	875091-59-1	875091-60-4
	875091-61-5	875091-62-6	875091-63-7	875091-64-8	875091-65-9
	875091-66-0	875091-67-1	875091-68-2	875091-69-3	875091-70-6
	875091-71-7	875091-72-8	875091-73-9	875091-74-0	875091-75-1
	875091-76-2	875091-77-3	875091-78-4	875091-80-8	875091-81-9

875091-82-0	875091-83-1	875091-84-2	875091-85-3	875091-86-4
875091-87-5	875091-88-6	875091-89-7	875091-90-0	875091-91-1
875091-92-2	875091-93-3	875091-94-4	875091-95-5	875091-96-6
875091-97-7	875091-98-8	875091-99-9	875092-00-5	875092-01-6
875092-02-7	875092-03-8	875092-04-9	875092-05-0	875092-06-1
875092-07-2	875092-08-3	875092-09-4	875092-10-7	875092-11-8
875092-12-9	875092-13-0	875092-14-1	875092-15-2	875092-16-3
875092-17-4	875092-18-5	875092-19-6	875092-20-9	875092-21-0
875092-22-1	875092-23-2	875092-24-3	875092-26-5	875092-28-7
875092-30-1	875092-32-3	875092-34-5	875092-36-7	875092-38-9
875092-40-3	875092-42-5	875092-44-7	875092-46-9	875092-48-1
875092-50-5	875092-52-7	875092-57-2	875092-72-1	875092-74-3
875092-78-7	875092-83-4	875092-88-9	875092-90-3	875092-95-8
875092-98-1	875093-25-7	875093-28-0	875093-30-4	875093-56-4
875093-58-6	875093-61-1	875093-69-9	875093-76-8	875093-85-9
875093-90-6	875093-95-1	875094-64-7	875094-98-7	875095-08-2
875095-15-1	875095-22-0	875095-35-5	875095-42-4	875095-45-7
875095-47-9	875095-53-7	875095-55-9	875095-57-1	
875095-59-3	875095-67-3	875095-73-1	875095-76-4	875095-98-0
875096-07-4	875096-12-1	875096-14-3	875096-19-8	875096-20-1
875096-21-2	875096-22-3	875096-23-4	875096-24-5	875096-25-6
875096-26-7	875096-27-8	875096-28-9	875096-29-0	875096-30-3
875096-31-4	875096-32-5	875096-33-6	875096-34-7	875096-35-8

RL: PRP (Properties)

(unclaimed protein sequence; genome sequence of human coronavirus HKU1 causing respiratory tract infection and its uses in diagnosis and treatment of infections)

IT	875098-76-3	875098-77-4	875098-78-5	875098-79-6	875098-80-9
	875098-81-0	875098-82-1	875098-83-2	875098-84-3	875098-85-4
	875098-86-5	875098-87-6	875098-88-7	875098-89-8	875098-90-1
	875098-91-2	875098-92-3	875098-93-4	875098-94-5	875098-95-6
	875098-96-7	875098-97-8	875098-98-9	875098-99-0	875099-00-6
	875099-01-7	875099-02-8	875099-03-9	875099-04-0	875099-05-1
	875099-06-2	875099-07-3	875099-08-4	875099-09-5	875099-10-8
	875099-11-9	875099-12-0	875099-13-1	875099-14-2	875099-15-3
	875099-16-4	875099-17-5	875099-18-6	875099-19-7	875099-20-0
	875099-21-1	875099-22-2	875099-23-3	875099-24-4	875099-25-5
	875099-26-6	875099-27-7	875099-28-8	875099-31-3	875099-64-2
	875099-67-5	875099-70-0	875099-77-7	875099-80-2	875099-88-0
	875099-90-4	875099-93-7	875099-97-1	875100-00-8	875100-03-1
	875100-05-3	875100-07-5	875100-07-5	875100-11-1	875100-45-1
	875100-56-4	875100-60-0	875100-70-2	875100-77-9	875100-81-5
	875100-88-2	875100-93-9	875100-95-1	875100-98-4	
	875101-01-2	875101-04-5	875101-06-7	875101-15-8	875101-27-2
	875101-30-7	875101-33-0	875101-37-4	875101-40-9	875101-42-1
	875101-44-3	875101-47-6	875101-49-8	875101-53-4	875101-61-4
	875101-63-6	875101-65-8	875101-69-2	875101-75-0	875101-77-2
	875101-82-9	875101-84-1	875101-86-3	875101-91-0	875101-93-2
	875101-96-5	875102-01-5	875102-03-7	875102-05-9	875102-07-1
	875102-09-3	875102-11-7	875102-14-0	875102-16-2	875102-18-4
	875102-19-5	875102-24-2	875102-28-6	875102-30-0	875102-32-2
	875102-34-4	875102-36-6	875102-39-9	875102-41-3	875102-48-0
	875102-50-4	875102-58-2	875102-60-6	875102-62-8	875102-64-0
	875102-68-4	875102-70-8	875102-72-0	875102-75-3	875102-76-4
	875102-78-6	875102-80-0	875102-82-2	875102-85-5	875102-90-2
	875102-92-4	875102-94-6	875102-97-9	875102-99-1	875103-01-8
	875103-04-1	875103-08-5	875103-11-0	875103-13-2	875103-16-5
	875103-19-8	875103-24-5	875103-28-9	875103-30-3	875103-32-5
	875103-37-0	875103-39-2	875103-41-6	875103-44-9	875103-47-2
	875103-49-4	875103-51-8	875103-53-0	875103-55-2	875103-57-4
	875103-59-6	875103-63-2	875103-65-4	875103-68-7	875103-70-1
	875103-73-4	875103-75-6	875103-77-8	875103-80-3	875103-82-5
	875103-83-6	875103-84-7	875103-85-8	875103-86-9	875103-87-0
	875103-88-1	875103-90-5	875103-92-7	875103-93-8	875103-94-9
	875103-95-0	875103-96-1	875103-97-2	875103-98-3	875103-99-4

875104-00-0	875104-01-1	875104-02-2	875104-04-4	875104-05-5
875104-06-6	875104-08-8	875104-10-2	875104-13-5	875104-14-6
875104-16-8	875104-18-0	875104-19-1	875104-20-4	875104-21-5
875104-22-6	875104-24-8	875104-27-1	875104-29-3	875104-32-8
875104-34-0	875104-36-2	875104-38-4	875104-39-5	875104-41-9
875104-43-1	875104-44-2	875104-45-3	875104-47-5	875104-48-6
875104-49-7	875104-50-0	875104-53-3	875104-55-5	875104-56-6
875104-57-7	875104-58-8	875104-59-9	875104-60-2	875104-61-3
875104-63-5	875104-65-7	875104-66-8	875104-67-9	875104-68-0
875104-69-1	875104-70-4	875104-71-5	875104-72-6	875104-73-7

RL: PRP (Properties)

(unclaimed protein sequence; genome sequence of human coronavirus HKU1 causing respiratory tract infection and its uses in diagnosis and treatment of infections)

=> d his

(FILE 'HOME' ENTERED AT 15:34:26 ON 16 MAY 2006)

FILE 'REGISTRY' ENTERED AT 15:34:39 ON 16 MAY 2006

L1 1060 S LPY/SQSP AND SQL<=15

FILE 'CAPLUS' ENTERED AT 15:35:33 ON 16 MAY 2006

L2 713 S L1  
L3 707975 S TUMOR? OR CANCER? OR NEOPLAS?  
L4 103 S L2 (L) L3  
L5 8 S L4 AND LIPOSOM?  
L6 1 S L5 NOT PY>2003  
L7 3311 S NASOPHARYNGEAL  
L8 3 S L7 AND L2

=> s l2 and NPC

2784 NPC  
445 NPC  
2902 NPC  
(NPC OR NPC)

L9 2 L2 AND NPC

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	22.44	56.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 15:38:49 ON 16 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11 KOREAPAT updates resume  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would  
like to better understand what you find useful. Please take  
approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:44:46 ON 18 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s lpy/SQSP

L1 159373 LPY/SQSP

=> s l1 and SQL=<10

622645 SQL=<10

L2 656 L1 AND SQL=<10

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

33.65

33.86

FILE 'CAPLUS' ENTERED AT 11:45:45 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 16 May 2006 (20060516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 521 L2

=> s cancer? or neoplas? or tumor?

292904 CANCER?

449273 NEOPLAS?

427701 TUMOR?

L4 708462 CANCER? OR NEOPLAS? OR TUMOR?

=> s 13 and 14

L5 218 L3 AND L4

=> s 13 (1) 14

L6 91 L3 (L) L4

=> s 16 not py>2002

3859922 PY>2002

L7 30 L6 NOT PY>2002

=> d ibib 1-8

L7 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:200078 CAPLUS

DOCUMENT NUMBER: 140:229427

TITLE: Cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1

INVENTOR(S): Schultze, Joachim L.; Vonderheide, Robert H.; Sherr, David; Nadler, Lee M.; Maecker, Britta; Von Bergwelt-Baildon, Michael

PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA; Trustees of Boston University

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE



-----	-----	-----	-----
WO 2001035810	A2	20010525	WO 2000-US31513
WO 2001035810	A3	20020110	20001115
W: CA, JP, US			
RW: AT, BE, CH, PT, SE, TR			
CA 2390882	AA	20010525	CA 2000-2390882
EP 1241945	A2	20020925	EP 2000-980436
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
PRIORITY APPLN. INFO.:		US 1999-165590P	P 19991115
		WO 2000-US31513	W 20001115

L7 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:486038 CAPLUS  
 DOCUMENT NUMBER: 138:66278  
 TITLE: Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine  
 AUTHOR(S): Erba, E.; Bassano, L.; Di Liberti, G.; Muradore, I.; Chiorino, G.; Ubezio, P.; Vignati, S.; Codegoni, A.; Desiderio, M. A.; Faircloth, G.; Jimeno, J.; D'Incalci, M.  
 CORPORATE SOURCE: Cancer Pharmacology Laboratory, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, 20157, Italy  
 SOURCE: British Journal of Cancer (2002), 86(9), 1510-1517  
 CODEN: BJCAAI; ISSN: 0007-0920  
 PUBLISHER: Nature Publishing Group  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:469230 CAPLUS  
 DOCUMENT NUMBER: 138:32948  
 TITLE: DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program  
 AUTHOR(S): Xu, Zhiyuan; Chen, Zhong-Ping; Malapetsa, Areti; Alaoui-Jamall, Moulay; Bergeron, Josee; Monks, Anne; Myers, Timothy G.; Mohr, Gérard; Sausville, Edward A.; Scudiero, Dominic A.; Aloyz, Raquel; Panasci, Lawrence C.  
 CORPORATE SOURCE: Lady Davis Institute for Medical Research, Sir Mortimer B Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Can.  
 SOURCE: Anti-Cancer Drugs (2002), 13(5), 511-519  
 CODEN: ANTDEV; ISSN: 0959-4973  
 PUBLISHER: Lippincott Williams & Wilkins  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:261896 CAPLUS  
 DOCUMENT NUMBER: 136:353907  
 TITLE: Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anti-tumor immunity in murine P815 model  
 AUTHOR(S): Wu, Yuzhang; Wan, Ying; Bian, Jiang; Zhao, Jianping; Jia, ZhengCai; Zhou, Liyun; Zhou, Wei; Tan, Yang  
 CORPORATE SOURCE: The Institute of Immunology, The Third Medicine University, Chungking, 400038, Peop. Rep. China

SOURCE: International Journal of Cancer (2002), 98(5), 748-753  
CODEN: IJCNAW; ISSN: 0020-7136  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:348043 CAPLUS  
DOCUMENT NUMBER: 135:120918  
TITLE: Epitope spreading upon P815 tumor rejection triggered  
by vaccination with the single class I MHC-restricted  
peptide P1A  
AUTHOR(S): Markiewicz, Mary A.; Fallarino, Francesca; Ashikari,  
Andrew; Gajewski, Thomas F.  
CORPORATE SOURCE: Departments of Pathology, Committee on Immunology,  
University of Chicago, Chicago, IL, 60637, USA  
SOURCE: International Immunology (2001), 13(5), 625-632  
CODEN: INIMEN; ISSN: 0953-8178  
PUBLISHER: Oxford University Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:678462 CAPLUS  
DOCUMENT NUMBER: 133:348838  
TITLE: The B subunit of shiga toxin fused to a tumor antigen  
elicits CTL and targets dendritic cells to allow MHC  
class I-restricted presentation of peptides derived  
from exogenous antigens  
AUTHOR(S): Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset,  
Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne,  
Valerie; Regnault, Armelle; Desaymard, Catherine;  
Amigorena, Sebastian; Ricciardi-Castagnoli, Paola;  
Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger;  
Tartour, Eric  
CORPORATE SOURCE: Unite d'Immunologie Clinique, Institut de la Sante et  
de la Recherche Medicale, Unite 255, Universite Pierre  
et Marie Curie, Institut Curie, Paris, 75248, Fr.  
SOURCE: Journal of Immunology (2000), 165(6), 3301-3308  
CODEN: JOIMA3; ISSN: 0022-1767  
PUBLISHER: American Association of Immunologists  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:673031 CAPLUS  
DOCUMENT NUMBER: 134:221118  
TITLE: Immunogenicity of tumor peptides: Importance of  
peptide length and stability of peptide/MHC class II  
complex  
AUTHOR(S): Grohmann, Ursula; Belladonna, Maria Laura; Bianchi,  
Roberta; Orabona, Ciriana; Silla, Silvia;  
Squillacioti, Giuseppe; Fioretti, Maria Cristina;  
Puccetti, Paolo  
CORPORATE SOURCE: Department of Experimental Medicine, Pharmacology  
Section, University of Perugia, Giochetto, I-06126,  
Italy  
SOURCE: Cancer Immunology Immunotherapy (1999), 48(4), 195-203  
CODEN: CIIMDN; ISSN: 0340-7004

PUBLISHER: Springer-Verlag  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:227537 CAPLUS  
DOCUMENT NUMBER: 132:262172  
TITLE: Use of neoangiogenesis markers for diagnosis and  
treatment of tumors  
INVENTOR(S): Krause, Werner; Muschick, Peter  
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
WO 2000018439	A3	20000914		
W:	AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
DE 19845798	A1	20000413	DE 1998-19845798	19980929
PRIORITY APPLN. INFO.:			DE 1998-19845798	A 19980929

=> d kwic 7

L7 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
IT 145882-36-6 329687-10-7 329687-11-8 329687-12-9  
329687-13-0  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(immunogenicity of tumor peptides and the importance of  
peptide length and stability of peptide/MHC class II complex)

=> d kwic 6

L7 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN  
IT 138831-86-4DP, fusion protein with Shiga toxin B subunit  
145882-36-6DP, fusion protein with Shiga toxin B subunit  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
(B subunit of Shiga toxin fused to a tumor antigen elicits  
CTL and targets dendritic cells to allow MHC class I-restricted  
presentation of peptides derived from exogenous antigens)

=> d his

(FILE 'HOME' ENTERED AT 11:44:46 ON 18 MAY 2006)

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 18 MAY 2006

L1 159373 S LPY/SQSP

L2 656 S L1 AND SQL=<10

FILE 'CAPLUS' ENTERED AT 11:45:45 ON 18 MAY 2006

L3 521 S L2  
L4 708462 S CANCER? OR NEOPLAS? OR TUMOR?  
L5 218 S L3 AND L4  
L6 91 S L3 (L) L4  
L7 30 S L6 NOT PY>2002

=> s deliver? or target?

281372 DELIVER?

471201 TARGET?

L8 724854 DELIVER? OR TARGET?

=> s l8 and l7

L9 7 L8 AND L7

=> d ibib 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:200078 CAPLUS

DOCUMENT NUMBER: 140:229427

TITLE: Cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1

INVENTOR(S): Schultze, Joachim L.; Vonderheide, Robert H.; Sherr, David; Nadler, Lee M.; Maecker, Britta; Von Bergwelt-Baildon, Michael

PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA; Trustees of Boston University

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035810	A2	20010525	WO 2000-US31513	20001115
WO 2001035810	A3	20020110		
W: CA, JP, US				
RW: AT, BE, CH, PT, SE, TR				
CA 2390882	AA	20010525	CA 2000-2390882	20001115
EP 1241945	A2	20020925	EP 2000-980436	20001115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 1999-165590P P 19991115

WO 2000-US31513 W 20001115

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:678462 CAPLUS

DOCUMENT NUMBER: 133:348838

TITLE: The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens

AUTHOR(S): Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset, Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne, Valerie; Regnault, Armelle; Desaymard, Catherine; Amigorena, Sebastian; Ricciardi-Castagnoli, Paola; Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger; Tartour, Eric

CORPORATE SOURCE: Unite d'Immunologie Clinique, Institut de la Sante et de la Recherche Medicale, Unite 255, Universite Pierre

SOURCE: et Marie Curie, Institut Curie, Paris, 75248, Fr.  
Journal of Immunology (2000), 165(6), 3301-3308  
CODEN: JOIMA3; ISSN: 0022-1767  
PUBLISHER: American Association of Immunologists  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:549173 CAPLUS  
DOCUMENT NUMBER: 131:175084  
TITLE: Pharmaceutical formulation of a didemnin compound  
INVENTOR(S): Beijnen, Jacob Hendrik; Nuyen, Bastiaan; Henrar,  
Roland Elizabeth Cornelis; Gomez, Andres; Jimeno, Jose  
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain; Ruffles, Graham Keith  
SOURCE: PCT Int. Appl., 12 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942125	A1	19990826	WO 1999-GB511	19990218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321116	AA	19990826	CA 1999-2321116	19990218
AU 9925389	A1	19990906	AU 1999-25389	19990218
AU 754073	B2	20021107		
BR 9908088	A	20001031	BR 1999-8088	19990218
EP 1054686	A1	20001129	EP 1999-905091	19990218
EP 1054686	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002503704	T2	20020205	JP 2000-532139	19990218
AT 217532	E	20020615	AT 1999-905091	19990218
PT 1054686	T	20020930	PT 1999-905091	19990218
ES 2175940	T3	20021116	ES 1999-905091	19990218
HK 1032538	A1	20021206	HK 2001-103194	20010507
PRIORITY APPLN. INFO.:			GB 1998-3448	A 19980218
			WO 1999-GB511	W 19990218
REFERENCE COUNT: 3			THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:123663 CAPLUS  
DOCUMENT NUMBER: 130:310353  
TITLE: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity  
AUTHOR(S): Toda, Masahiro; Rabkin, Samuel D.; Kojima, Hidefumi; Martuza, Robert L.  
CORPORATE SOURCE: Georgetown Brain Tumor Center and Department of Neurosurgery, Georgetown University Medical Center, Washington, DC, 20007, USA  
SOURCE: Human Gene Therapy (1999), 10(3), 385-393  
CODEN: HGTHE3; ISSN: 1043-0342

PUBLISHER: Mary Ann Liebert, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:13451 CAPLUS  
DOCUMENT NUMBER: 130:236141  
TITLE: Improved efficacy of dendritic cell vaccines and  
successful immunization with tumor antigen  
peptide-pulsed peripheral blood mononuclear cells by  
coadministration of recombinant murine interleukin-12  
AUTHOR(S): Fallarino, Francesca; Uyttenhove, Catherine; Boon,  
Thierry; Gajewskii, Thomas F.  
CORPORATE SOURCE: Department of Pathology, University of Chicago,  
Chicago, IL, USA  
SOURCE: International Journal of Cancer (1999), 80(2), 324-333  
CODEN: IJCNAW; ISSN: 0020-7136  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1995:531867 CAPLUS  
DOCUMENT NUMBER: 123:74098  
TITLE: Generation of a drug resistance profile by  
quantitation of mdr-1/P-glycoprotein in the cell lines  
of the National Cancer Institute Anticancer Drug  
Screen  
AUTHOR(S): Alvarez, Manuel; Paull, Ken; Monks, Anne; Hose,  
Curtis; Lee, Jong-Seok; Weinstein, John; Grever, Mike;  
Bates, Susan; Fojo, Tito  
CORPORATE SOURCE: Lab. Mol. Pharmacol., Developmtl. Therapeutics  
Program, National Cancer Institute, National  
Institutes Health, Bethesda, MD, 20892, USA  
SOURCE: Journal of Clinical Investigation (1995), 95(5),  
2205-14  
CODEN: JCINAO; ISSN: 0021-9738  
PUBLISHER: Rockefeller University Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1995:519394 CAPLUS  
DOCUMENT NUMBER: 122:263156  
TITLE: Synthetic oligonucleotide expressed by a recombinant  
vaccinia virus elicits therapeutic CTL  
AUTHOR(S): Irvine, Kari R.; McCabe, Barbra Jill; Rosenberg,  
Steven A.; Restifo, Nicholas P.  
CORPORATE SOURCE: Surgery Branch, Natl. Inst. Health, Bethesda, MD,  
20892, USA  
SOURCE: Journal of Immunology (1995), 154(9), 4651-7  
CODEN: JOIMA3; ISSN: 0022-1767  
PUBLISHER: American Association of Immunologists  
DOCUMENT TYPE: Journal  
LANGUAGE: English

=> d ibib kwic 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:200078 CAPLUS

DOCUMENT NUMBER: 140:229427  
 TITLE: Cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1  
 INVENTOR(S): Schultze, Joachim L.; Vonderheide, Robert H.; Sherr, David; Nadler, Lee M.; Maecker, Britta; Von Bergwelt-Baildon, Michael  
 PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA; Trustees of Boston University  
 SOURCE: PCT Int. Appl., 120 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035810	A2	20010525	WO 2000-US31513	20001115
WO 2001035810	A3	20020110		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2390882	AA	20010525	CA 2000-2390882	20001115
EP 1241945	A2	20020925	EP 2000-980436	20001115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				

PRIORITY APPLN. INFO.: US 1999-165590P P 19991115  
 WO 2000-US31513 W 20001115

AB This invention is based on the discovery that cytochrome P 450 1B1 (CYP1B1) includes peptides that bind to HLA mols. Antigen-presenting cells that present such peptides on their surfaces, in complexes with HLA, can activate cytotoxic T lymphocytes (CTLs) to specifically lyse cells expressing CYP1B1, in an MHC-restricted fashion. Based on observations that CYP1B1 is a mediator of dioxin-related effects on tumorigenesis, CYP1B1 is identified as a potential universal tumor antigen; it is over-expressed in nearly 100% of human tumors, whereas the expression in normal tissue is low. Thus, the invention provides methods for the immunotherapeutic targeting of CYP1B1-expressing cells, such as cancer cells, and methods of monitoring the efficacy of such therapeutic methods. The invention provides methods for conducting cancer immunotherapy and diagnosis using cytochrome P 450 1B1 and peptide fragments thereof, as well as cotreatment with a second or third tumor-associated antigen (e.g., telomerase).

IT 330596-22-0, Cytochrome P 450 1B1 344835-77-4 433304-00-8  
 622837-65-4 622837-66-5 663892-54-4 663892-55-5 663892-56-6  
 663892-57-7 663892-58-8 663892-59-9 663892-60-2  
 663892-61-3 663892-62-4 663892-63-5 663892-64-6 663892-65-7  
 663892-66-8 663892-67-9 663892-68-0 663892-69-1 663892-70-4  
 663892-71-5 663892-72-6 663892-73-7 663892-74-8 663892-75-9  
 663892-76-0 663892-77-1 663892-78-2 663892-79-3 663892-80-6  
 663892-81-7 663892-82-8 663892-83-9 663892-84-0 663892-85-1  
 663892-86-2 663892-87-3 663892-88-4 663892-89-5 663892-90-8  
 663892-91-9 663892-92-0 663892-93-1 663892-94-2 663892-95-3  
 663892-96-4 663892-97-5 663892-98-6 663892-99-7  
 663893-00-3 663893-01-4 663893-02-5 663893-03-6 663893-04-7  
 663893-05-8 663893-06-9 663893-07-0 663893-08-1 663893-09-2  
 663893-10-5 663893-11-6 663893-12-7 663893-13-8 663893-14-9  
 663893-15-0 663893-16-1 663893-17-2 663893-18-3 663893-19-4  
 663893-20-7 663893-21-8 663893-22-9 663893-23-0 663893-24-1  
 663893-25-2 663893-26-3 663893-27-4 663893-28-5 663893-29-6  
 663893-30-9 663893-31-0 663893-32-1 663893-33-2 663893-34-3  
 663893-35-4 663893-36-5 663893-37-6 663893-38-7 663893-39-8  
 663893-40-1 663893-41-2 663893-42-3 663893-43-4 663893-44-5  
 663893-45-6 663893-46-7 663893-47-8 663893-48-9 663893-49-0  
 663893-50-3 663893-51-4 663893-52-5 663893-53-6 663893-54-7

663893-55-8	663893-56-9	663893-57-0	663893-58-1	663893-59-2
663893-60-5	663893-61-6	663893-62-7	663893-63-8	663893-64-9
663893-65-0	663893-66-1	663893-67-2	663893-68-3	663893-69-4
663893-70-7	663893-71-8	663893-72-9	663893-73-0	663893-74-1
663893-75-2	663893-76-3	663893-77-4	663893-78-5	663893-79-6
663893-80-9	663893-81-0	663893-82-1	663893-83-2	663893-84-3
663893-85-4	663893-86-5	663893-87-6	663893-88-7	663893-89-8
663893-90-1	663893-91-2	663893-92-3	663893-93-4	663893-94-5
663893-95-6	663893-96-7	663893-97-8	663893-98-9	663893-99-0
663894-00-6	663894-01-7	663894-02-8	663894-03-9	663894-04-0
663894-05-1	663894-06-2	663894-07-3	663894-08-4	663894-09-5
663894-10-8	663894-11-9	663894-12-0	663894-13-1	663894-14-2
663894-15-3	663894-16-4	663894-17-5	663894-18-6	663894-19-7
663894-20-0	663894-21-1	663894-22-2	663894-23-3	663894-24-4
663894-25-5	663894-26-6	663894-27-7	663894-28-8	663894-29-9
663894-30-2	663894-31-3	663894-32-4	663894-33-5	663894-34-6
663894-35-7	663894-36-8	663894-37-9	663894-38-0	
663894-39-1	663894-40-4	663894-41-5	663894-42-6	663894-43-7
663894-44-8	663894-45-9	663894-46-0	663894-47-1	663894-48-2
663894-49-3	663894-50-6	663894-51-7	663894-52-8	663894-53-9
663894-54-0	663894-55-1	663894-56-2	663894-57-3	663894-58-4
663894-59-5	663894-60-8	663894-61-9	663894-62-0	663894-63-1
663894-64-2	663894-65-3	663894-66-4	663894-67-5	663894-68-6
663894-69-7	663894-70-0	663894-71-1	663894-72-2	663894-73-3
663894-74-4	663894-75-5	663894-76-6	663894-77-7	663894-78-8
663894-79-9	663894-80-2	663894-81-3	663894-82-4	

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT	663894-83-5	663894-84-6	663894-85-7	663894-86-8	663894-87-9
	663894-88-0	663894-89-1	663894-90-4	663894-91-5	663894-92-6
	663894-93-7	663894-94-8	663894-95-9	663894-96-0	663894-97-1
	663894-98-2	663894-99-3	663895-00-9	663895-01-0	663895-02-1
	663895-03-2	663895-04-3	663895-05-4	663895-06-5	663895-07-6
	663895-08-7	663895-09-8	663895-10-1	663895-11-2	663895-12-3
	663895-13-4	663895-14-5	663895-15-6	663895-16-7	663895-17-8
	663895-18-9	663895-19-0	663895-20-3	663895-21-4	663895-22-5
	663895-23-6	663895-24-7	663895-25-8	663895-26-9	663895-27-0
	663895-28-1	663895-29-2	663895-30-5	663895-31-6	
	663895-32-7	663895-33-8	663895-34-9	663895-35-0	663895-36-1
	663895-37-2	663895-38-3	663895-39-4	663895-40-7	663895-41-8
	663895-42-9	663895-43-0	663895-44-1	663895-45-2	663895-46-3
	663895-47-4	663895-48-5	663895-49-6	663895-50-9	663895-51-0
	663895-52-1	663895-53-2	663895-54-3	663895-55-4	663895-56-5
	663895-57-6	663895-58-7	663895-59-8	663895-60-1	663895-61-2
	663895-62-3	663895-63-4	663895-64-5	663895-65-6	663895-66-7
	663895-67-8	663895-68-9	663895-69-0	663895-70-3	663895-71-4
	663895-72-5	663895-73-6	663895-74-7	663895-75-8	663895-76-9
	663895-77-0	663895-78-1	663895-79-2	663895-80-5	663895-81-6
	663895-82-7	663895-83-8	663895-84-9	663895-85-0	663895-86-1
	663895-87-2	663895-88-3	663895-89-4	663895-90-7	663895-91-8
	663895-92-9	663895-93-0	663895-94-1	663895-95-2	663895-96-3
	663895-97-4	663895-98-5	663895-99-6	663896-00-2	663896-01-3
	663896-02-4	663896-03-5	663896-04-6	663896-05-7	663896-06-8
	663896-07-9	663896-08-0	663896-09-1	663896-10-4	663896-11-5
	663896-12-6	663896-13-7	663896-14-8	663896-15-9	663896-16-0
	663896-17-1	663896-18-2	663896-19-3	663896-20-6	663896-21-7
	663896-22-8	663896-23-9	663896-24-0	663896-25-1	663896-26-2
	663896-27-3	663896-28-4	663896-29-5	663896-30-8	663896-32-0
	663896-34-2	663896-35-3	663896-36-4	663896-37-5	663896-38-6
	663896-39-7	663896-40-0	663896-41-1	663896-42-2	663896-43-3
	663896-44-4	663896-45-5	663896-46-6	663896-47-7	663896-48-8
	663896-49-9	663896-50-2	663896-51-3	663896-52-4	663896-53-5
	663896-54-6	663896-55-7	663896-56-8	663896-57-9	663896-58-0



663896-59-1	663896-60-4	663896-61-5	663896-62-6	663896-63-7
663896-64-8	663896-65-9	663896-66-0	663896-67-1	663896-68-2
663896-69-3	663896-70-6	663896-71-7	663896-72-8	663896-73-9
663896-74-0	663896-75-1	663896-76-2	663896-77-3	663896-78-4
663896-79-5	663896-80-8	663896-81-9	663896-82-0	663896-83-1
663896-84-2	663896-85-3	663896-86-4	663896-87-5	663896-88-6
663896-89-7	663896-90-0	663896-91-1	663896-92-2	663896-93-3
663896-94-4	663896-95-5	663896-96-6	663896-97-7	663896-98-8
663896-99-9	663897-00-5	663897-01-6	663897-02-7	663897-03-8
663897-04-9	663897-05-0	663897-06-1	663897-07-2	663897-08-3
663897-09-4	663897-10-7	663897-11-8	663897-12-9	663897-13-0
663897-14-1	663897-15-2	663897-16-3	663897-17-4	663897-18-5

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT	663897-19-6	663897-20-9	663897-21-0	663897-22-1	
	663897-23-2	663897-24-3	663897-25-4	663897-26-5	663897-27-6
	663897-28-7	663897-29-8	663897-30-1	663897-31-2	663897-32-3
	663897-33-4	663897-34-5	663897-35-6	663897-36-7	663897-37-8
	663897-38-9	663897-39-0	663897-40-3	663897-41-4	663897-42-5
	663897-43-6	663897-44-7	663897-45-8	663897-46-9	663897-47-0
	663897-48-1	663897-49-2	663897-50-5	663897-51-6	663897-52-7
	663897-53-8	663897-54-9	663897-55-0	663897-56-1	663897-57-2
	663897-58-3	663897-59-4	663897-60-7	663897-61-8	663897-62-9
	663897-63-0	663897-64-1	663897-65-2	663897-66-3	663897-67-4
	663897-68-5	663897-69-6	663897-71-0	663897-72-1	663897-73-2
	663897-74-3	663897-75-4	663897-76-5	663897-77-6	663897-78-7
	663897-79-8	663897-80-1	663897-81-2	663897-82-3	663897-83-4
	663897-84-5	663897-85-6	663897-86-7	663897-87-8	663897-88-9
	663897-89-0	663897-90-3	663897-91-4	663897-92-5	663897-93-6
	663897-94-7	663897-95-8	663897-96-9	663897-97-0	663897-98-1
	663897-99-2	663898-00-8	663898-01-9	663898-02-0	663898-03-1
	663898-04-2	663898-05-3	663898-06-4	663898-07-5	663898-08-6
	663898-09-7	663898-10-0	663898-11-1	663898-12-2	663898-13-3
	663898-14-4	663898-15-5	663898-16-6	663898-17-7	663898-18-8
	663898-19-9	663898-20-2	663898-21-3	663898-22-4	663898-23-5
	663898-24-6	663898-26-8	663898-27-9	663898-28-0	
	663898-29-1	663898-30-4	663898-31-5	663898-32-6	663898-33-7
	663898-34-8	663898-35-9	663898-36-0	663898-37-1	663898-38-2
	663898-39-3	663898-40-6	663898-41-7	663898-42-8	663898-43-9
	663898-44-0	663898-45-1	663898-46-2	663898-47-3	663898-48-4
	663898-49-5	663898-50-8	663898-51-9	663898-52-0	
	663898-53-1	663898-54-2	663898-55-3	663898-56-4	663898-57-5
	663898-58-6	663898-59-7	663898-60-0	663898-61-1	663898-62-2
	663898-63-3	663898-64-4	663898-65-5	663898-66-6	663898-67-7
	663898-68-8	663898-69-9	663898-70-2	663898-71-3	
	663898-72-4	663898-73-5	663898-74-6	663898-75-7	663898-76-8
	663898-77-9	663898-78-0	663898-79-1	663898-80-4	663898-81-5
	663898-82-6	663898-83-7	663898-84-8	663898-85-9	663898-86-0
	663898-87-1	663898-88-2	663898-89-3	663898-90-6	663898-91-7
	663898-92-8	663898-93-9	663898-94-0	663898-95-1	663898-96-2
	663898-97-3	663898-98-4	663899-00-1	663899-01-2	663899-02-3
	663899-03-4	663899-04-5	663899-05-6	663899-06-7	663899-07-8
	663899-08-9	663899-09-0	663899-10-3	663899-11-4	663899-12-5
	663899-13-6	663899-14-7	663899-15-8	663899-16-9	663899-17-0
	663899-18-1	663899-19-2	663899-20-5	663899-21-6	663899-22-7
	663899-23-8	663899-24-9	663899-25-0	663899-26-1	663899-27-2
	663899-28-3	663899-29-4	663899-30-7	663899-31-8	663899-32-9
	663899-34-1	663899-36-3	663899-39-6	663899-41-0	663899-43-2
	663899-45-4	663899-47-6	663899-49-8	663899-50-1	663899-51-2
	663899-52-3	663899-53-4	663899-54-5	663899-55-6	663899-56-7
	663899-57-8	663899-59-0	663899-61-4	663899-63-6	663899-65-8
	663899-67-0	663899-69-2	663899-71-6		

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP

(Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cancer immunotherapy and diagnosis using immunogenic  
peptides from human cytochrome P 450 1B1)

IT	663899-73-8	663899-75-0	663899-77-2	663899-79-4	663899-81-8
	663899-83-0	663899-85-2	663899-87-4	663899-88-5	663899-89-6
	663899-90-9	663899-91-0	663899-92-1	663899-93-2	663899-94-3
	663899-95-4	663899-96-5	663899-97-6	663899-98-7	663899-99-8
	663900-00-3	663900-01-4	663900-02-5	663900-03-6	
	663900-04-7	663900-05-8	663900-06-9	663900-07-0	663900-08-1
	663900-09-2	663900-10-5	663900-11-6	663900-12-7	663900-13-8
	663900-14-9	663900-15-0	663900-16-1	663900-17-2	663900-18-3
	663900-19-4	663900-20-7	663900-21-8	663900-22-9	663900-23-0
	663900-24-1	663900-25-2	663900-26-3	663900-27-4	663900-28-5
	663900-29-6	663900-30-9	663900-31-0	663900-32-1	
	663900-33-2	663900-34-3	663900-35-4	663900-36-5	663900-37-6
	663900-38-7	663900-39-8	663900-40-1	663900-41-2	663900-42-3
	663900-43-4	663900-45-6	663900-46-7	663900-47-8	663900-49-0
	663900-51-4	663900-52-5	663900-54-7	663900-55-8	663900-56-9
	663900-57-0	663900-58-1	663900-59-2	663900-60-5	663900-61-6
	663900-62-7	663900-63-8	663900-64-9	663900-65-0	663900-66-1
	663900-67-2	663900-68-3	663900-69-4	663900-70-7	663900-71-8
	663900-72-9	663900-73-0	663900-74-1	663900-75-2	663900-76-3
	663900-77-4	663900-78-5	663900-79-6	663900-80-9	663900-81-0
	663900-82-1	663900-83-2	663900-84-3	663900-85-4	663900-86-5
	663900-87-6	663900-88-7	663900-89-8	663900-90-1	663900-91-2
	663900-92-3	663900-93-4	663900-94-5	663900-95-6	
	663900-96-7	663900-97-8	663900-98-9	663900-99-0	663901-00-6
	663901-01-7	663901-02-8	663901-03-9	663901-04-0	663901-05-1
	663901-06-2	663901-07-3	663901-08-4	663901-09-5	663901-10-8
	663901-11-9	663901-12-0	663901-13-1	663901-14-2	663901-15-3
	663901-16-4	663901-17-5	663901-18-6	663901-19-7	663901-20-0
	663901-21-1	663901-22-2	663901-23-3	663901-24-4	663901-25-5
	663901-26-6	663901-27-7	663901-28-8	663901-29-9	663901-30-2
	663901-31-3	663901-32-4	663901-33-5	663901-34-6	663901-35-7
	663901-36-8	663901-37-9	663901-38-0	663901-39-1	663901-40-4
	663901-41-5	663901-42-6	663901-43-7	663901-44-8	663901-45-9
	663901-46-0	663901-48-2	663901-50-6	663901-51-7	663901-52-8
	663901-53-9	663901-54-0	663901-55-1	663901-56-2	663901-57-3
	663901-58-4	663901-59-5	663901-60-8	663901-61-9	
	663901-62-0	663901-63-1	663901-64-2	663901-65-3	663901-66-4
	663901-67-5	663901-68-6	663901-69-7	663901-70-0	663901-71-1
	663901-72-2	663901-73-3	663901-74-4	663901-75-5	663901-76-6
	663901-77-7	663901-78-8	663901-79-9	663901-80-2	663901-81-3
	663901-82-4	663901-83-5	663901-84-6	663901-85-7	663901-86-8
	663901-87-9	663901-88-0	663901-89-1	663901-90-4	663901-91-5
	663901-92-6	663901-93-7	663901-94-8	663901-95-9	663901-96-0
	663901-97-1	663901-98-2	663901-99-3	663902-00-9	663902-01-0
	663902-02-1	663902-03-2	663902-04-3	663902-05-4	663902-06-5
	663902-07-6	663902-08-7	663902-09-8	663902-10-1	663902-11-2
	663902-12-3	663902-13-4	663902-14-5	663902-15-6	663902-16-7
	663902-17-8	663902-18-9	663902-19-0		

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP  
(Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cancer immunotherapy and diagnosis using immunogenic  
peptides from human cytochrome P 450 1B1)

IT	663902-20-3	663902-21-4	663902-22-5	663902-23-6	663902-24-7
	663902-25-8	663902-26-9	663902-27-0	663902-28-1	663902-29-2
	663902-30-5	663902-31-6	663902-32-7	663902-33-8	663902-34-9
	663902-35-0	663902-36-1	663902-37-2	663902-38-3	663902-39-4
	663902-40-7	663902-41-8	663902-42-9	663902-43-0	663902-44-1
	663902-45-2	663902-46-3	663902-47-4	663902-48-5	663902-49-6
	663902-50-9	663902-51-0	663902-52-1	663902-53-2	663902-54-3
	663902-55-4	663902-57-6	663902-59-8	663902-61-2	663902-63-4
	663902-64-5	663902-65-6	663902-66-7	663902-67-8	663902-68-9
	663902-69-0	663902-70-3	663902-71-4	663902-72-5	663902-73-6

663902-74-7	663902-75-8	663902-76-9	663902-77-0	663902-78-1
663902-79-2	663902-80-5	663902-81-6	663902-82-7	663902-83-8
663902-84-9	663902-85-0	663902-86-1	663902-87-2	663902-88-3
663902-89-4	663902-90-7	663902-91-8	663902-92-9	663902-93-0
663902-94-1	663902-95-2	663902-96-3	663902-97-4	663902-98-5
663902-99-6	663903-00-2	663903-01-3	663903-02-4	663903-03-5
663903-04-6	663903-05-7	663903-06-8	663903-07-9	663903-08-0
663903-09-1	663903-10-4	663903-11-5	663903-12-6	663903-13-7
663903-14-8	663903-15-9	663903-16-0	663903-17-1	663903-18-2
663903-19-3	663903-20-6	663903-21-7	663903-22-8	663903-23-9
663903-24-0	663903-25-1	663903-26-2	663903-27-3	663903-28-4
663903-29-5	663903-30-8	663903-31-9	663903-32-0	663903-33-1
663903-34-2	663903-35-3	663903-36-4	663903-37-5	
663903-38-6	663903-39-7	663903-40-0	663903-41-1	663903-42-2
663903-43-3	663903-44-4	663903-45-5	663903-46-6	663903-47-7
663903-48-8	663903-49-9	663903-50-2	663903-51-3	663903-52-4
663903-53-5	663903-54-6	663903-55-7	663903-56-8	663903-57-9
663903-58-0	663903-59-1	663903-60-4	663903-61-5	663903-62-6
663903-63-7	663903-64-8	663903-65-9	663903-66-0	663903-67-1
663903-68-2	663903-69-3	663903-70-6	663903-71-7	663903-72-8
663903-73-9	663903-74-0	663903-75-1	663903-76-2	663903-82-0
663903-94-4	663903-95-5	663903-96-6	663904-09-4	663904-11-8
663904-12-9	663904-13-0	663904-14-1	663904-15-2	663904-18-5
663904-22-1	663904-23-2	663904-24-3	663904-25-4	663904-26-5
663904-27-6	663904-28-7	663904-29-8	663904-30-1	663904-32-3
663904-33-4	663904-34-5	663904-48-1	663904-49-2	663904-57-2
663904-58-3	663904-62-9	663904-91-4	663904-93-6	663905-46-2
663905-47-3	663905-48-4	663905-49-5	663905-50-8	663905-51-9
663905-52-0	663905-53-1	663905-54-2	663905-55-3	663905-56-4
663905-57-5	663905-58-6	663905-59-7	663905-60-0	663905-61-1
663905-62-2	663905-63-3	663905-64-4	663905-65-5	663905-66-6
663905-67-7	663905-68-8	663905-69-9	663905-72-4	
663905-75-7	663905-76-8	663905-78-0	663905-80-4	663905-81-5
663905-82-6	663905-83-7	663905-84-8	663905-85-9	663905-86-0
663905-87-1	663905-88-2	663905-89-3	663905-90-6	663905-91-7
663905-92-8	663905-93-9	663905-94-0	663905-95-1	663905-96-2
663905-97-3	663905-98-4	663905-99-5	663906-00-1	663906-01-2
663906-02-3				

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT	663906-03-4	663906-04-5	663906-05-6	663906-06-7	
	663906-07-8	663906-08-9	663906-09-0	663906-10-3	663906-11-4
	663906-13-6	663906-14-7	663906-15-8	663906-16-9	663906-17-0
	663906-18-1	663906-19-2	663906-20-5	663906-21-6	663906-22-7
	663906-23-8	663906-25-0	663906-27-2	663906-29-4	663906-31-8
	663906-32-9	663906-33-0	663906-34-1	663906-35-2	663906-36-3
	663906-37-4	663906-38-5	663906-39-6	663906-40-9	663906-41-0
	663906-42-1	663906-43-2	663906-44-3	663906-45-4	663906-46-5
	663906-47-6	663906-48-7	663906-49-8	663906-50-1	663906-51-2
	663906-52-3	663906-53-4	663906-54-5	663906-55-6	663906-56-7
	663906-57-8	663906-59-0	663906-60-3	663906-61-4	663906-62-5
	663906-63-6	663906-64-7	663906-65-8	663906-66-9	663906-67-0
	663906-68-1	663906-69-2	663906-70-5	663906-71-6	663906-72-7
	663906-73-8	663906-74-9	663906-75-0	663906-76-1	663906-77-2
	663906-78-3	663906-79-4	663906-80-7	663906-81-8	663906-82-9
	663906-83-0	663906-84-1	663906-85-2	663906-86-3	663906-87-4
	663906-88-5	663906-89-6	663906-90-9	663906-91-0	663906-92-1
	663906-93-2	663906-94-3	663906-95-4	663906-96-5	663906-97-6
	663906-98-7	663906-99-8	663907-00-4	663907-01-5	663907-02-6
	663907-03-7	663907-04-8	663907-05-9	663907-06-0	663907-07-1
	663907-08-2	663907-09-3	663907-10-6	663907-11-7	663907-12-8
	663907-16-2	663907-19-5	663907-22-0	663907-26-4	663907-30-0
	663907-31-1	663907-32-2	663907-33-3	663907-34-4	663907-35-5

663907-36-6	663907-37-7	663907-38-8	663907-39-9	663907-40-2
663907-41-3	663907-42-4	663907-43-5	663907-44-6	663907-45-7
663907-46-8	663907-47-9	663907-48-0	663907-49-1	663907-50-4
663907-51-5	663907-52-6	663907-53-7	663907-54-8	663907-55-9
663907-56-0	663907-57-1	663907-58-2	663907-59-3	663907-60-6
663907-61-7	663907-62-8	663907-63-9	663907-64-0	663907-65-1
663907-66-2	663907-67-3	663907-68-4	663907-69-5	663907-70-8
663907-71-9	663907-72-0	663907-73-1	663907-74-2	663907-75-3
663907-76-4	663907-77-5	663907-78-6	663907-79-7	663907-80-0
663907-81-1	663907-82-2	663907-83-3	663907-84-4	663907-85-5
663907-86-6	663907-87-7	663907-88-8	663907-89-9	663907-90-2
663907-91-3	663907-92-4	663907-93-5	663907-94-6	663907-95-7
663907-96-8	663907-97-9	663907-98-0	663907-99-1	663908-00-7
663908-01-8	663908-02-9	663908-03-0	663908-04-1	663908-05-2
663908-06-3	663908-07-4	663908-08-5	663908-09-6	663908-10-9
663908-11-0	663908-12-1	663908-13-2	663908-14-3	663908-15-4
663908-16-5	663908-17-6	663908-18-7	663908-19-8	663908-20-1
663908-21-2	663908-22-3	663908-23-4	663908-24-5	663908-25-6
663908-26-7	663908-27-8	663908-28-9	663908-29-0	663908-30-3
663908-31-4	663908-32-5	663908-33-6	663908-34-7	663908-35-8
663908-36-9	663908-37-0	663908-38-1	663908-39-2	663908-40-5
663908-41-6	663908-42-7	663908-43-8	663908-44-9	663908-46-1
663908-47-2	663908-48-3	663908-49-4	663908-50-7	663908-51-8
663908-52-9	663908-53-0	663908-54-1	663908-55-2	663908-56-3

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT	663908-57-4	663908-58-5	663908-59-6	663908-60-9	663908-61-0
	663908-62-1	663908-63-2	663908-65-4	663908-67-6	663908-68-7
	663908-69-8	663908-70-1	663908-72-3	663908-74-5	663908-76-7
	663908-79-0	663908-81-4	663908-83-6	663908-85-8	663908-87-0
	663908-88-1	663908-90-5	663908-92-7	663908-94-9	663908-95-0
	663908-96-1	663908-98-3	663909-00-0	663909-01-1	663909-04-4
	663909-07-7	663909-08-8	663909-10-2	663909-11-3	663909-13-5
	663909-16-8	663909-19-1	663909-22-6	663909-24-8	663909-26-0
	663909-29-3	663909-31-7	663909-32-8	663909-33-9	663909-34-0
	663909-35-1	663909-36-2	663909-37-3	663909-38-4	663909-39-5
	663909-40-8	663909-41-9	663909-42-0	663909-43-1	663909-44-2
	663909-45-3	663909-46-4	663909-47-5	663909-48-6	663909-49-7
	663909-50-0	663909-51-1	663909-52-2	663909-53-3	663909-54-4
	663909-55-5	663909-56-6	663909-57-7	663909-58-8	663909-59-9
	663909-60-2	663909-61-3	663909-62-4	663909-63-5	663909-64-6
	663909-65-7	663909-66-8	663909-67-9	663909-68-0	663909-69-1
	663909-70-4	663909-71-5	663909-72-6	663909-73-7	663909-74-8
	663909-75-9	663909-76-0	663909-77-1	663909-78-2	663909-79-3
	663909-80-6	663909-83-9	663909-86-2	663909-89-5	663909-92-0
	663909-95-3	663909-98-6	663910-00-7	663910-01-8	

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:678462 CAPLUS

DOCUMENT NUMBER: 133:348838

TITLE: The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens

AUTHOR(S): Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset, Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne, Valerie; Regnault, Armelle; Desaymard, Catherine; Amigorena, Sebastian; Ricciardi-Castagnoli, Paola; Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger;

CORPORATE SOURCE: Tartour, Eric  
 Unite d'Immunologie Clinique, Institut de la Sante et  
 de la Recherche Medicale, Unite 255, Universite Pierre  
 et Marie Curie, Institut Curie, Paris, 75248, Fr.  
 SOURCE: Journal of Immunology (2000), 165(6), 3301-3308  
 CODEN: JOIMA3; ISSN: 0022-1767  
 PUBLISHER: American Association of Immunologists  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 63

THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

- TI The B subunit of shiga toxin fused to a tumor antigen elicits CTL and  
 targets dendritic cells to allow MHC class I-restricted  
 presentation of peptides derived from exogenous antigens
- AB Immunization with peptide or recombinant proteins generally fails to  
 elicit CTL, which are thought to play a key role in the control of  
 virus-infected cells and tumor growth. In this study we show that the  
 nontoxic B subunit of Shiga toxin fused to a tumor peptide derived from  
 the mouse mastocytoma P815 can induce specific CTL in mice without the use  
 of adjuvant. The Shiga B subunit acts as a vector rather than as an  
 adjuvant, because coinjection of the tumor peptide and the B subunit as  
 sep. entities does not lead to CTL induction. We also demonstrated that  
 in vitro the B subunit mediates the delivery of various  
 exogenous CD8 T cell epitopes into the conventional MHC class I-restricted  
 pathway, as this process is inhibited by brefeldin A and lactacystin and  
 requires a functional TAP system. In contrast to other nonviral methods  
 for transport of exogenous Ags into the endogenous MHC class I pathway  
 that involve macropinocytosis or phagocytosis, the Shiga B subunit  
 targets this pathway in a receptor-dependent manner, namely via  
 binding to the glycolipid Gb3. Because this receptor is highly expressed  
 on various dendritic cells, it should allow preferential targeting  
 of the Shiga B subunit to these professional APCs. Therefore, the Shiga B  
 subunit appears to represent an attractive vector for vaccine development  
 due to its ability to target dendritic cells and to induce  
 specific CTL without the need for adjuvant.
- IT Antigen presentation  
 Dendritic cell  
 Genetic vectors  
 MHC restriction  
 (B subunit of Shiga toxin fused to a tumor antigen elicits CTL and  
 targets dendritic cells to allow MHC class I-restricted  
 presentation of peptides derived from exogenous antigens)
- IT Toxins  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological  
 process); BSU (Biological study, unclassified); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
 (Shiga, B subunit, fusion protein with tumor antigen; B subunit of  
 Shiga toxin fused to a tumor antigen elicits CTL and targets  
 dendritic cells to allow MHC class I-restricted presentation of  
 peptides derived from exogenous antigens)
- IT Proteins, specific or class  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (TAP-1 (transporter in antigen processing 1); B subunit of Shiga toxin  
 fused to a tumor antigen elicits CTL and targets dendritic  
 cells to allow MHC class I-restricted presentation of peptides derived  
 from exogenous antigens and requirement for)
- IT Immunostimulants  
 (adjuvants; B subunit of Shiga toxin fused to a tumor antigen elicits  
 CTL and targets dendritic cells to allow MHC class  
 I-restricted presentation of peptides derived from exogenous antigens  
 in absence of)
- IT T cell (lymphocyte)  
 (cytotoxic; B subunit of Shiga toxin fused to a tumor antigen elicits  
 CTL and targets dendritic cells to allow MHC class

I-restricted presentation of peptides derived from exogenous antigens)  
 IT 138831-86-4DP, fusion protein with Shiga toxin B subunit  
 145882-36-6DP, fusion protein with Shiga toxin B subunit  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)  
 (B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)  
 IT 71965-57-6, Globotriaosylceramide  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens via binding to)

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN.

ACCESSION NUMBER: 1999:549173 CAPLUS  
 DOCUMENT NUMBER: 131:175084  
 TITLE: Pharmaceutical formulation of a didemnin compound  
 INVENTOR(S): Beijnen, Jacob Hendrik; Nuyen, Bastiaan; Henrar, Roland Elizabeth Cornelis; Gomez, Andres; Jimeno, Jose  
 PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain; Ruffles, Graham Keith  
 SOURCE: PCT Int. Appl., 12 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942125	A1	19990826	WO 1999-GB511	19990218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321116	AA	19990826	CA 1999-2321116	19990218
AU 9925389	A1	19990906	AU 1999-25389	19990218
AU 754073	B2	20021107		
BR 9908088	A	20001031	BR 1999-8088	19990218
EP 1054686	A1	20001129	EP 1999-905091	19990218
EP 1054686	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002503704	T2	20020205	JP 2000-532139	19990218
AT 217532	E	20020615	AT 1999-905091	19990218
PT 1054686	T	20020930	PT 1999-905091	19990218
ES 2175940	T3	20021116	ES 1999-905091	19990218
HK 1032538	A1	20021206	HK 2001-103194	20010507
PRIORITY APPLN. INFO.:			GB 1998-3448	A 19980218
			WO 1999-GB511	W 19990218
REFERENCE COUNT: 3			THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

IT Drug delivery systems  
 (parenterals, freeze-dried; lyophilized parenteral pharmaceuticals containing didemnin compds. for cancer treatment)  
 IT 69-65-8, D-Mannitol 110342-52-4, Didemnin 137219-37-5, Aplidine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lyophilized parenteral pharmaceuticals containing didemnin compds. for  
cancer treatment)

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN / .  
ACCESSION NUMBER: 1999:123663 CAPLUS  
DOCUMENT NUMBER: 130:310353  
TITLE: Herpes simplex virus as an in situ cancer vaccine for  
the induction of specific anti-tumor immunity  
AUTHOR(S): Toda, Masahiro; Rabkin, Samuel D.; Kojima, Hidefumi;  
Martuza, Robert L.  
CORPORATE SOURCE: Georgetown Brain Tumor Center and Department of  
Neurosurgery, Georgetown University Medical Center,  
Washington, DC, 20007, USA  
SOURCE: Human Gene Therapy (1999), 10(3), 385-393  
CODEN: HGTHE3; ISSN: 1043-0342  
PUBLISHER: Mary Ann Liebert, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The success of cancer gene therapy is likely to require the  
targeting of multiple antitumor mechanisms. One strategy involves  
the use of attenuated, replication-competent virus vectors, such as herpes  
simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in  
human tumor cells with resultant cell death and tumor growth inhibition,  
yet is nonpathogenic in normal tissue. In this study, we demonstrate that  
infection of established tumors with G207 also induces a highly specific  
systemic anti-tumor immune response. In a syngeneic, bilateral  
established s.c. tumor model, with mouse CT26 colorectal carcinoma cells  
in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral  
inoculation with G207 caused a significant reduction in the growth of both the  
inoculated and contralateral noninoculated tumors. This elicited  
anti-tumor response is dependent on viral infection of the tumor, as  
intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor  
growth. Treatment of s.c. CT26 tumors by intratumoral inoculation of G207  
induced a tumor-specific T cell response. CD8+ cytotoxic T lymphocyte  
(CTL) activity was generated that recognized a dominant "tumor-specific"  
major histocompatibility complex (MHC) class I-restricted epitope (AHL)  
from CT26 cells. In immune-competent animals, G207 is acting as an in  
situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to  
inhibit tumor growth both by local cytotoxic viral replication in tumor  
cells and induction of a systemic anti-tumor immune response.  
IT 145882-36-6P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN  
(Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC  
(Process)  
(herpes simplex virus as an in situ cancer vaccine for  
induction of specific anti-tumor immunity and recognition of  
mastocytoma P815 antigenic peptide)

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:13451 CAPLUS  
DOCUMENT NUMBER: 130:236141  
TITLE: Improved efficacy of dendritic cell vaccines and  
successful immunization with tumor antigen  
peptide-pulsed peripheral blood mononuclear cells by  
coadministration of recombinant murine interleukin-12  
AUTHOR(S): Fallarino, Francesca; Uyttenhove, Catherine; Boon,  
Thierry; Gajewskii, Thomas F.  
CORPORATE SOURCE: Department of Pathology, University of Chicago,  
Chicago, IL, USA  
SOURCE: International Journal of Cancer (1999), 80(2), 324-333  
CODEN: IJCNW; ISSN: 0020-7136  
PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The well-characterized P815 tumor model was used to optimize anti-tumor immunization approaches in mice. Tumor peptides derived from antigens P198 or P1A were targeted to antigen-presenting cells (APC) by ex vivo pulsing. Initial expts. with irradiated pulsed splenic dendritic cells (sDC) injected weekly in the hind footpads for 3 wk demonstrated cytolytic T lymphocyte (CTL) generation in 10-20% of mice. Because of the importance of interleukin-12 (IL-12) in tumor rejection responses, pulsed sDCs also were given together with recombinant murine IL-12 (rmIL-12). This strategy induced peptide-specific CTL in 100% of the mice. The IL-12 had to be injected in the footpads on days 0, 1 and 2 of each immunization week to achieve an optimal effect. The improvement seen with the addition of IL-12 prompted examination of other sources of APC. Purified resting B cells, lipopolysaccharide (LPS) blasts and non-fractionated splenocytes or peripheral blood mononuclear cells (PBMC) were pulsed with peptide and administered with the same schedule of rmIL-12. Because these cell types appeared to bind peptides less avidly than did DC, increasing peptide doses were used during pulsing. Interestingly, immunization with each of these APC also induced specific CTL in 100% of mice, provided rmIL-12 was coadministered. CTLs were detected both in the spleen and in the peripheral blood. Immunization with irradiated, P1A-pulsed PBMC plus rmIL-12 resulted in protection against challenge with tumors expressing the specific antigen in all mice. The ease by which human patient PBMCs can be prepared provides a straightforward vaccination approach to be used in clin. trials of peptide-based immunization in melanoma.

IT 136671-85-7P 145882-36-6P  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (dendritic cell vaccines and immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12)

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:531867 CAPLUS  
DOCUMENT NUMBER: 123:74098  
TITLE: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

AUTHOR(S): Alvarez, Manuel; Paull, Ken; Monks, Anne; Hose, Curtis; Lee, Jong-Seok; Weinstein, John; Grever, Mike; Bates, Susan; Fojo, Tito

CORPORATE SOURCE: Lab. Mol. Pharmacol., Developmtl. Therapeutics Program, National Cancer Institute, National Institutes Health, Bethesda, MD, 20892, USA

SOURCE: Journal of Clinical Investigation (1995), 95(5), 2205-14

CODEN: JCINAO; ISSN: 0021-9738

PUBLISHER: Rockefeller University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Identifying new chemotherapeutic agents and characterizing mechanisms of resistance may improve cancer treatment. The Anticancer Drug Screen of the National Cancer Institute uses 60 cell lines to identify new agents. Expression of mdr-1/P-glycoprotein was measured by quant. PCR. Expression was detected in 39 cell lines; the highest levels were in renal and colon carcinomas. Expression was also detected in all melanomas and central nervous system tumors, but in only one ovarian carcinoma and one leukemia cell line. Using a modified version of the COMPARE program, a high correlation was found between expression of mdr-1 and cellular resistance to a large number of compds. Evidence that these compds. are P-glycoprotein



substrates includes: (a) enhancement of cytotoxicity by verapamil; (b) demonstration of cross-resistance in a multidrug-resistant cell line, (c) ability to antagonize P-glycoprotein, increasing vinblastine accumulation by decreasing efflux; and (d) inhibition of photoaffinity labeling by azidopine. Identification of many heretofore unrecognized compds. as substrates indicates that P-glycoprotein has a broader substrate specificity than previously recognized. This study confirms the validity of this novel approach and provides the basis for similar studies examining a diverse group of gene products, including other resistance mechanisms, putative drug targets, and genes involved in the cell cycle and apoptosis.

IT 50-44-2, 6-Mercaptopurine 50-76-0, Actinomycin D 51-21-8,  
5-Fluorouracil 52-24-4, Thiotepe 52-53-9, Verapamil 55-86-7,  
Nitrogen mustard 59-05-2, Methotrexate 127-07-1, Hydroxyurea  
147-94-4, Cytosine arabinoside 148-82-3, Melphalan 154-93-8, BCNU  
305-03-3, Chlorambucil 512-64-1, NSC 526417 865-21-4, Vinblastine  
5853-29-2, (-)-Cephaeline dihydrochloride 7059-24-7, Chromomycin A3  
11006-70-5, Olivomycin 13010-47-4, CCNU 15663-27-1, Cisplatinum  
20830-81-3, Daunomycin 25316-40-9, Adriamycin 29767-20-2, VM-26  
33069-62-4, Taxol 33419-42-0, VP-16 41451-75-6, Bruceantin  
51264-14-3, Amsacrine 53142-03-3, NSC 646428 62816-98-2, Tetraplatin  
63166-73-4, Phyllanthoside 63521-85-7 64725-24-2, Deoxybouvardin  
64755-14-2, Bouvardin 65548-52-9, NSC 649087 71439-68-4, Bisantrone  
hydrochloride 77327-05-0, NSC 325319 80790-68-7 81552-36-5,  
Trioxacarcin A 86825-99-2 88254-07-3 110417-88-4, NSC 376128  
123830-79-5, NSC 355644 130760-07-5, NSC 624332 131251-67-7, NSC  
633320 133091-36-8, NSC 626852 153264-95-0 160262-47-5, NSC 640085  
160338-75-0, NSC 172946 165169-10-8, NSC 80467 165169-11-9, NSC 353076  
165169-12-0, NSC 620308 165169-13-1, NSC 637905 165169-14-2, NSC  
645806 165169-15-3, NSC 648785 165198-36-7, NSC 648114 165198-37-8,  
NSC 346243 165198-38-9, NSC 626316 165198-39-0, NSC 344003  
165290-33-5, NSC 643179

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(generation of a drug resistance profile by quantitation of  
mdr-1/P-glycoprotein in the cell lines of the National Cancer  
Institute Anticancer Drug Screen)

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:519394 CAPLUS

DOCUMENT NUMBER: 122:263156

TITLE: Synthetic oligonucleotide expressed by a recombinant  
vaccinia virus elicits therapeutic CTL

AUTHOR(S): Irvine, Kari R.; McCabe, Barbara Jill; Rosenberg,  
Steven A.; Restifo, Nicholas P.

CORPORATE SOURCE: Surgery Branch, Natl. Inst. Health, Bethesda, MD,  
20892, USA

SOURCE: Journal of Immunology (1995), 154(9), 4651-7  
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

IT Antigens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(p815A; tumor rejection by cytotoxic T-cells is induced by vaccinia  
virus encoding endoplasmic reticulum-targeted peptide of)

IT Endoplasmic reticulum

Vaccines

(tumor rejection by cytotoxic T-cells is induced by vaccinia virus  
encoding endoplasmic reticulum-targeted peptide of  
tumor-associated antigen)

IT Histocompatibility antigens

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)

(MHC (major histocompatibility antigen complex), class I, tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum-targeted peptide of tumor-associated antigen)

IT Lymphocyte  
(T-cell, cytotoxic, vaccinia virus encoding endoplasmic reticulum-targeted tumor-associated antigenic peptide induces tumor rejection by)

IT Antigens  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor-associated, tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum-targeted peptide of)

IT Virus, animal  
(vaccinia, tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum-targeted peptide of tumor-associated antigen)

IT 145882-36-6  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum-targeted peptide of tumor-associated antigen)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	51.43	85.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 11:50:35 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock

NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
 NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
 visualization results  
 NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
 NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
 NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
 NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
 NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
 NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
 NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
 thesaurus added in PCTFULL  
 NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
 NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
 NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display  
 in MARPAT  
 NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
 second quarter; strategies may be affected  
 NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
 NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8  
 NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\*\*\*\*\*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would  
 like to better understand what you find useful. Please take  
 approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you  
 will be entered in a drawing to win a free iPod(R). Your responses  
 will be kept confidential and will help us make future improvements  
 to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:42:48 ON 18 MAY 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:42:56 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0
DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```

*****
*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005.  A new display format, IDERL, is now
* available and contains the CA role and document type information.
*
*****

```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s LPY/SQSP.
L1      159373 LPY/SQSP
```

```
=> s l1 and SQL=<100
      9239723 SQL=<100
L2      9302 L1.AND SQL=<100
```

```

=> s 137219-37-5 or 663892-58-8 or 663892-97-5 or 663894-35-7 or 663895-27-0
      1 137219-37-5
        (137219-37-5/RN)
      1 663892-58-8
        (663892-58-8/RN)
      1 663892-97-5
        (663892-97-5/RN)
      1 663894-35-7
        (663894-35-7/RN)
      1 663895-27-0
        (663895-27-0/RN)
L3      5 137219-37-5 OR 663892-58-8 OR 663892-97-5 OR 663894-35-7 OR
        663895-27-0

```

=> s 12 and 13  
L4                      5 L2 AND L3

=> d sql seq 1-5

L4 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
SQL 9

SEQ 1 PNLPHYVLAFL

===

HITS AT: 3-5

L4 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
SQL 9

SEQ 1 DQPNLPHYVL

===

HITS AT: 5-7

L4 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
SQL 9

SEQ 1 GDQPNLPHYV

===

HITS AT: 6-8

L4 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
SQL 9

SEQ 1 NLPYVLAFL

===

HITS AT: 2-4

L4 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
SQL 8

SEQ 1 PLTXLPHY

===

HITS AT: 6-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

=> d cn sql seq 1-5

L4 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
CN L-Phenylalanine, L-prolyl-L-asparaginyl-L-leucyl-L-prolyl-L-tyrosyl-L-  
valyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 26: PN: W00135810 SEQID: 276 claimed protein  
SQL 9

SEQ 1 PNLPHYVLAFL

===

HITS AT: 3-5

L4 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
CN L-Leucine, L- $\alpha$ -aspartyl-L-glutaminyl-L-prolyl-L-asparaginyl-L-leucyl-  
L-prolyl-L-tyrosyl-L-valyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 51: PN: W00135810 SEQID: 184 claimed protein  
SQL 9

SEQ 1 DQPNLPHYVL

===

HITS AT: 5-7

L4 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN  
CN L-Valine, glycyl-L- $\alpha$ -aspartyl-L-glutaminyl-L-prolyl-L-asparaginyl-L-

leucyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 6: PN: W00135810 SEQID: 46 claimed protein

SQL 9

SEQ 1 GDQPNLPYV

===

HITS AT: 6-8

L4 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN

CN L-Leucine, L-asparaginyL-L-leucyl-L-prolyl-L-tyrosyl-L-valyl-L-leucyl-L-alanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 7: PN: W00135810 SEQID: 6 claimed protein

SQL 9

SEQ 1 NLPYVLAFL

===

HITS AT: 2-4

L4 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN

CN DidemnA, N-[1-(1,2-dioxopropyl)-L-prolyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 15H-Pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosine, cyclic peptide deriv.

OTHER NAMES:

CN Aplidin

CN Aplidine

CN DehydroidemnA B

CN Plitidepsin

SQL 8

SEQ 1 PLTXXL PY

===

HITS AT: 6-8

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

93.77

93.98

STN INTERNATIONAL LOGOFF AT 13:45:31 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 16 MAY 10 CA/Caplus enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11 KOREAPAT updates resume  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would  
like to better understand what you find useful. Please take  
approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you  
will be entered in a drawing to win a free iPod(R). Your responses  
will be kept confidential and will help us make future improvements  
to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006

=> file reg.		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6  
DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s lpy/SQSP  
L1 159373 LPY/SQSP  
  
=> s l1 and SQL=<20  
3919358 SQL=<20  
L2 1357 L1 AND SQL=<20

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	33.65	33.86

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.



PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 17 May 2006 (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 881 L2

=> s cancer? or tumor? or neoplas?

292904 CANCER?

427701 TUMOR?

449273 NEOPLAS?

L4 708462 CANCER? OR TUMOR? OR NEOPLAS?

=> s 13 (1) 14

L5 127 L3 (L) L4

=> s liposom?

L6 50046 LIPOSOM?

=> s 16 and 15

L7 8 L6 AND L5

=> s 17 not py>2002

3859922 PY>2002

L8 0 L7 NOT PY>2002

=> s 13 and 14

L9 312 L3 AND L4

=> s 19 and 16

L10 21 L9 AND L6

=> s 110 not py>2002

3859922 PY>2002

L11 1 L10 NOT PY>2002

=> d ibib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:511054 CAPLUS

DOCUMENT NUMBER: 131:149319

TITLE: Liposome fusion and delivery vehicle

INVENTOR(S): Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry M.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9939742	A1	19990812	WO 1999-US2410	19990204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6372720	B1	20020416	US 1998-19346	19980205
CA 2325744	AA	19990812	CA 1999-2325744	19990204
AU 9925823	A1	19990823	AU 1999-25823	19990204
EP 1053024	A1	20001122	EP 1999-905726	19990204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1998-19346 A 19980205  
 WO 1999-US2410 W 19990204  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
 TI Liposome fusion and delivery vehicle  
 AB Described herein are liposome complexes and the individual components thereof for intracellular and/or intranuclear delivery of substances. Methods of use of the provided liposome complexes and components are also described. Generally, the liposome complexes described herein include a non-cationic lipid, a fusogenic peptide and a substance to be delivered to the cell and/or nucleus. In some of the liposome complexes described herein, the fusogenic peptide does not contain multiple pos. charges at neutral pH and above. In these liposome complexes, two addnl. components are used in assembling the liposome complex with DNA.  
 ST pharmaceutical liposome nucleic acid delivery;  
 tumor cell targeting pharmaceutical liposome  
 IT Pulmonary surfactant  
 (B peptide; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)  
 IT Plasmids  
 (DNA; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)  
 IT Neoplasm  
 (cells; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)  
 IT Embryo, animal  
 (chick; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)  
 IT Liposomes  
 (complexes, for intracellular and/or intranuclear delivery; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)  
 IT Gene, animal  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (for luciferase, expression of; liposome complexes and

individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Peptides, biological studies  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (fusogenic; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Animal cell  
 Cell nucleus  
 Cytoplasm  
 (liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Nucleic acids  
 Polyoxyalkylenes, biological studies  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT DNA  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (liposome complexes with; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Drug delivery systems  
 (liposomes, for cell targeting; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Lipids, biological studies  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (noncationic; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT Phospholipids, biological studies  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (zwitterionic or anionic; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT 9014-00-0, Luciferase  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (gene for, expression of; liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

IT 4004-05-1, Dioleoylphosphatidylethanolamine 4235-95-4 25322-68-3  
 56750-90-4 125056-56-6 236093-94-0 236093-95-1 236093-96-2  
 236093-97-3 236093-98-4 236093-99-5 236094-00-1 236094-01-2  
 236094-02-3 236094-04-5 236094-05-6 236094-06-7  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (liposome complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
16.61	50.47

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6  
DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s 236094-02-3
L12      1 236094-02-3
          (236094-02-3/RN)
```

=> d his

(FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006

```
L1      159373 S LPY/SQSP
L2      1357 S L1 AND SQL=<20
```

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006

```
L3      881 S L2
L4      708462 S CANCER? OR TUMOR? OR NEOPLAS?
L5      127 S L3 (L) L4
L6      50046 S LIPOSOM?
L7      8 S L6 AND L5
L8      0 S L7 NOT PY>2002
L9      312 S L3 AND L4
L10     21 S L9 AND L6
L11     1 S L10 NOT PY>2002
```

FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006

```
L12     1 S 236094-02-3
```

```
=> s l12 and l2
L13     1 L12 AND L2
```

=> d cn sql seq

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
CN L-Histidinamide, L-phenylalanyl-L-prolyl-L-isoleucyl-L-prolyl-L-leucyl-L-  
prolyl-L-tyrosyl-L-alanyl-L-tryptophyl-L-leucyl-L-cysteinyglycyl-L-lysyl-  
L-lysyl-L-lysyl-L-phenylalanyl-L-lysyl-L-leucyl-L-lysyl- (9CI) (CA INDEX  
NAME)  
SQL 20

SEQ 1 FPIPLPYAWL CGKKKFKLKH

HITS AT: 5-7

=>

=>  
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.24	57.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 14:11:03 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 14:48:11 ON 18 MAY 2006  
FILE 'REGISTRY' ENTERED AT 14:48:11 ON 18 MAY 2006  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.24	57.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

=> d his

(FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006

L1 159373 S LPY/SQSP  
L2 1357 S L1 AND SQL=<20

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006

L3 881 S L2  
 L4 708462 S CANCER? OR TUMOR? OR NEOPLAS?  
 L5 127 S L3 (L) L4  
 L6 50046 S LIPOSOM?  
 L7 8 S L6 AND L5  
 L8 0 S L7 NOT PY>2002  
 L9 312 S L3 AND L4  
 L10 21 S L9 AND L6  
 L11 1 S L10 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006

L12 1 S 236094-02-3  
 L13 1 S L12 AND L2

=> s l10 not py>2003  
 '2003' NOT A VALID FIELD CODE  
 15897 CANCER?  
 348992 TUMOR?  
 5424 NEOPLAS?  
 3 LIPOSOM?  
 0 PY>2003  
 L14 0 L10 NOT PY>2003

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	26.72	77.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'CAPLUS' ENTERED AT 14:49:03 ON 18 MAY 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21  
 FILE LAST UPDATED: 17 May 2006 (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l10 not py>2003  
 2790637 PY>2003  
 L15 3 L10 NOT PY>2003

=> d ibib 1-3

L15 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:950032 CAPLUS  
 DOCUMENT NUMBER: 140:19766

TITLE: Compositions containing the SP(1-4) polypeptide, or  
NEP antisense sequences and antibodies, and methods  
for the regulation of proliferation of stem cells  
INVENTOR(S): Rameshwar, Pranela  
PATENT ASSIGNEE(S): University of Medicine & Dentistry of New Jersey, USA  
SOURCE: U.S. Pat. Appl. Publ., 42 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225010	A1	20031204	US 2002-154332	20020521
PRIORITY APPLN. INFO.:			US 2002-154332	20020521

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2001:12285 CAPLUS  
DOCUMENT NUMBER: 134:99563  
TITLE: HLA binding peptides and their uses  
INVENTOR(S): Sette, Alessandro; Sidney, John; Southwood, Scott  
PATENT ASSIGNEE(S): Epimmune Inc., USA  
SOURCE: PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000225	A1	20010104	WO 2000-US17842	20000628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2370413	AA	20010104	CA 2000-2370413	20000628
EP 1189624	A1	20020327	EP 2000-944976	20000628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003535024	T2	20031125	JP 2001-505934	20000628
PRIORITY APPLN. INFO.:			US 1999-141422P	P 19990629
			WO 2000-US17842	W 20000628
REFERENCE COUNT: 2			THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1999:511054 CAPLUS  
DOCUMENT NUMBER: 131:149319  
TITLE: Liposome fusion and delivery vehicle  
INVENTOR(S): Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry M.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9939742	A1	19990812	WO 1999-US2410	19990204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6372720	B1	20020416	US 1998-19346	19980205
CA 2325744	AA	19990812	CA 1999-2325744	19990204
AU 9925823	A1	19990823	AU 1999-25823	19990204
EP 1053024	A1	20001122	EP 1999-905726	19990204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1998-19346	A 19980205
			WO 1999-US2410	W 19990204
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

	SINCE FILE	TOTAL
=> file reg		
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	6.29	83.48
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-0.75

FILE 'REGISTRY' ENTERED AT 14:50:14 ON 18 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6  
DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and



predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his

(FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006

L1 159373 S LPY/SQSP  
L2 1357 S L1 AND SQL=<20

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006

L3 881 S L2  
L4 708462 S CANCER? OR TUMOR? OR NEOPLAS?  
L5 127 S L3 (L) L4  
L6 50046 S LIPOSOM?  
L7 8 S L6 AND L5  
L8 0 S L7 NOT PY>2002  
L9 312 S L3 AND L4  
L10 21 S L9 AND L6  
L11 1 S L10 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006

L12 1 S 236094-02-3  
L13 1 S L12 AND L2  
L14 0 S L10 NOT PY>2003

FILE 'CAPLUS' ENTERED AT 14:49:03 ON 18 MAY 2006

L15 3 S L10 NOT PY>2003

FILE 'REGISTRY' ENTERED AT 14:50:14 ON 18 MAY 2006

=> s l1 and SQL=<30  
5932094 SQL=<30  
L16 1681 L1 AND SQL=<30

=> s l16 and l2  
L17 1357 L16 AND L2

=> s l16 not l2  
L18 324 L16 NOT L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.64	89.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'CAPLUS' ENTERED AT 14:51:12 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21  
FILE LAST UPDATED: 17 May 2006 (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 118

L19 225 L18

=> s 119 and 14

L20 41 L19 AND L4

=> s 120 and 16

L21 1 L20 AND L6

=> d ibib

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:511054 CAPLUS

DOCUMENT NUMBER: 131:149319

TITLE: Liposome fusion and delivery vehicle

INVENTOR(S): Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry M.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9939742	A1	19990812	WO 1999-US2410	19990204
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6372720	B1	20020416	US 1998-19346	19980205
CA 2325744	AA	19990812	CA 1999-2325744	19990204
AU 9925823	A1	19990823	AU 1999-25823	19990204
EP 1053024	A1	20001122	EP 1999-905726	19990204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRIORITY APPLN. INFO.: US 1998-19346 A 19980205

WO 1999-US2410 W 19990204

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.06	91.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 14:52:26 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCTFULL  
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display  
in MARPAT  
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during  
second quarter; strategies may be affected  
NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11 KOREAPAT updates resume  
  
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:07:17 ON 18 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:07:25 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*

\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*



```

=> s chemother? or (anticancer or (anti (2W) cancer))
    76841 CHEMOTHER?
    35080 ANTICANCER
      46 ANTICANCERS
    35100 ANTICANCER
      (ANTICANCER OR ANTICANCERS)
    406221 ANTI
      9 ANTIS
    406228 ANTI
      (ANTI OR ANTIS)
    278734 CANCER
    40530 CANCERS
    289315 CANCER
      (CANCER OR CANCERS)
    6337 ANTI (2W) CANCER
L8    110362 CHEMOTHER? OR (ANTICANCER OR (ANTI (2W) CANCER))

```

```

=> s l8 and l7
L9    2 L8 AND L7

```

```

=> d ibib 1-2

```

```

L9    ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:    2006:193397  CAPLUS
DOCUMENT NUMBER:     144:272644
TITLE:               Anti-mortalin 2 antibody and functional ribonucleic
                     acids for treating cancer
INVENTOR(S):         Kaul, Renuwadhwa; Taira, Kazunari; Kaul, Sunil
PATENT ASSIGNEE(S):  National Institute of Advanced Industrial Scienceand
                     Technology, Japan
SOURCE:              PCT Int. Appl., 79 pp.
                     CODEN: PIXXD2
DOCUMENT TYPE:        Patent
LANGUAGE:             Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006022344	A1	20060302	WO 2005-JP15459	20050825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006089471	A2	20060406	JP 2005-242063	20050824
PRIORITY APPLN. INFO.:			JP 2004-246891	A 20040826
			JP 2005-242063	A 20050824
REFERENCE COUNT:	11	THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

```

L9    ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:    2002:220814  CAPLUS
DOCUMENT NUMBER:     136:259587
TITLE:               Novel tumor-associated marker
INVENTOR(S):         Trakht, Ilya; Canfield, Robert; Kalantarov, Gary;
                     Rudchenko, Sergei

```

PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New York, USA  
 SOURCE: PCT Int. Appl., 276 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022851	A2	20020321	WO 2001-US29242	20010918
WO 2002022851	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422828	AA	20020321	CA 2001-2422828	20010918
AU 2001092782	A5	20020326	AU 2001-92782	20010918
EP 1326894	A2	20030716	EP 2001-973176	20010918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518630	T2	20040624	JP 2002-527293	20010918
PRIORITY APPLN. INFO.:			US 2000-664958	A 20000918
			WO 2001-US29242	W 20010918

=> d kwic 2

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 IT Drug delivery systems  
 (liposomes; novel tumor-associated marker)  
 IT AIDS (disease)  
 Animal tissue  
 Apoptosis  
 Ascitic fluid  
 Autoimmune disease  
 Bacteremia  
 Blood analysis  
 Blood plasma  
 Blood serum  
 Bone marrow  
 Cerebrospinal fluid  
 Chemiluminescent substances  
 Chemotherapy  
 Chromosome  
 Concentration (process)  
 Cryopreservation  
 Cryptococcus (fungus)  
 Cryptococcus (insect)  
 Culture media  
 Drugs  
 Dyes  
 Ebola virus  
 Epitopes  
 Escherichia coli  
 Fluorescent substances  
 Fusion, biological  
 Genetic methods

Hantavirus  
 Human  
 Human T-lymphotropic virus 1  
 Human T-lymphotropic virus 2  
 Human herpesvirus  
 Human papillomavirus  
 Imaging agents  
 Immobilization, molecular or cellular  
 Immunity  
 Influenza virus  
 Klebsiella  
 Labels  
 Lupus erythematosus  
 Lymph  
 Lymphoma  
 Macrophage  
 Mammary gland  
 Melanoma  
 Mus  
 Neoplasm  
 Nucleic acid hybridization  
 Optical imaging devices  
 Precipitation (chemical)  
 Prostate gland  
 Protein sequences  
 Radiochemical analysis  
 Rheumatoid arthritis  
 Saliva  
 Sepsis  
 Septicemia  
 Staphylococcus  
 Streptococcus  
 Tear (ocular fluid)  
 Test kits  
 Testis, neoplasm  
 Tetanus  
 Urine analysis  
 Viremia

(novel tumor-associated marker)

IT 405011-18-9 405011-20-3 405011-22-5 405011-24-7 405011-64-5  
 405011-66-7 405011-69-0 405011-71-4 405011-73-6  
 405011-75-8 405011-77-0 405011-79-2

RL: PRP (Properties)

(unclaimed protein sequence; novel tumor-associated marker)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

20.97

50.07

FILE 'REGISTRY' ENTERED AT 16:11:12 ON 18 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s 405011-66-7 or 405011-69-0 or 405011-75-8 or 405011-77-0
      1 405011-66-7
        (405011-66-7/RN)
      1 405011-69-0
        (405011-69-0/RN)
      1 405011-75-8
        (405011-75-8/RN)
      1 405011-77-0
        (405011-77-0/RN)
L10      4 405011-66-7 OR 405011-69-0 OR 405011-75-8 OR 405011-77-0
```

=> d his

(FILE 'HOME' ENTERED AT 16:07:17 ON 18 MAY 2006)

```
L1      FILE 'REGISTRY' ENTERED AT 16:07:25 ON 18 MAY 2006
      159373'S LPY/SQSP
```

```
L2      FILE 'CAPLUS' ENTERED AT 16:07:44 ON 18 MAY 2006
      21611 S L1
L3      708462 S CANCER? OR TUMOR? OR NEOPLAS?
L4      3097 S L2 AND L3
L5      976 S L2 (L) L3
L6      50046 S LIPOSOM?
L7      21 S L5 AND L6
L8      110362 S CHEMOTHER? OR (ANTICANCER OR (ANTI (2W) CANCER))
L9      2 S L8 AND L7
```

```
L10     FILE 'REGISTRY' ENTERED AT 16:11:12 ON 18 MAY 2006
      4 S 405011-66-7 OR 405011-69-0 OR 405011-75-8 OR 405011-77-0
```

```
=> s l1 and l10
L11     4 L1 AND L10
```

```
=> s cn SQL SEQ 1-4
      17719 CN
      4522 CNS
      22240 CN
        (CN OR CNS)
      2 SQL
      17848 SEQ
      1 SEQS
```

```

17849 SEQ
      (SEQ OR SEQS)
18816078 1
16897302 4
L12      0 CN SQL SEQ 1-4
      (CN(W) SQL(W) SEQ(W) 1(W) 4)

=> s 111
L13      4 L1 AND L10

=> d cn SQL SEQ 1-4

L13 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
CN 21: PN: W00222851 FIGURE: 41B unclaimed protein (9CI) (CA INDEX NAME)
SQL 230

SEQ      1 RRMQYNRRFV NVVPTFGKKK GTTFTKIFVG GLPYHTTDAS LRKYFEGFGD
      ===
      51 IEEAVVITDR QTGKSRGYGF VMADRAAAE RACKDPNPII DGRKANVNLA
      101 YLGAKPWCLQ TGFAIGVQQL HPTLIQRTYG LTPHYIYPPA IVQPSVVIPA
      151 APVPSLSSPY IEYTPASPVY AQYPPATYDQ YPYAASPATA DSFVGYSYPAA
      201 AVHQALSAAA PAGTTFVQYQ APQLQPD RMQ
HITS AT: 32-34

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
CN 19: PN: W00222851 FIGURE: 41A unclaimed protein (9CI) (CA INDEX NAME)
SQL 229

SEQ      1 SAGFSRPLAA PGVMYGSQKG TTFTKIFVGG LPYHTTDASL RKYFEGFGDI
      ===
      51 EEAVVITDRQ TGKSRGYGFV TMADRAAAER ACKDPNPIID GRKANVNLAY
      101 LGAKPWCLQT GFAIGVQQLH PTLIQRTYGL TPHYIYPPAI VQPSVVIPAA
      151 PVPSSLSSPYI EYTPASPVYA QYPPATYDQY PYAASPATAD SFVGYSYPAA
      201 VHQALSAAAP AGTTFVQYQA PQLQPD RMQ
HITS AT: 31-33

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
CN 13: PN: W00222851 FIGURE: 38 unclaimed protein (9CI) (CA INDEX NAME)
SQL 197

SEQ      1 MMFPQSRHSG SSHLPQQLKF TTSDSCDRIK DEFQLLQAQY HSLKLECDKL
      51 ASEKSEMQRH YVMYYEMSYG LNIEMHKQAE IVKRLNGICA QVLPYLSQEH
      ===
      101 QQQVLGAIER AKQVTAPELN SIIRQQLQAH QLSQLQALAL PLTPLPVGLQ
      151 PPSLPAVSAG TGLLSLSALG SQAHLKEDK NGHDGDTHQE DDGEKSD
HITS AT: 93-95

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2006 ACS on STN
CN 11: PN: W00222851 FIGURE: 37 unclaimed protein (9CI) (CA INDEX NAME)
SQL 196

SEQ      1 MFPQSRHSGS SHLPQQLKFT TSDSCDRIKD EFQLLQAQYH SLKLECDKLA
      51 SEKSEMQRHY VMYEYMSYGL NIEMHKQAEI VKRLNGICAQ VLPYLSQEHQ
      ===
      101 QQVLGAIERA KQVTAPELNS IIRQQLQAHQ LSQQLQALALP LTPPLPVGLQP
      151 PSLPAVSAGT GLLSLSALGS QAHLKEDKN GHDGDTHQED DGEKSD
HITS AT: 92-94

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

```

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

51.00

101.07

STN INTERNATIONAL LOGOFF AT 16:13:34 ON 18 MAY 2006